

THOUGHTS ON ALS

RIKU MATTILA

RIKU MATTILA

Thoughts on ALS

KongoBooks

First edition

This book was professionally typeset on Reedsy.
Find out more at reedsy.com

Contents

Foreword

For more than a decade, I have been thinking about writing this book.

The idea began long before ALS became a public discussion point for me. It started when I first arrived at what was, at the time, a highly unconventional conclusion: that the dynamics of stress granules might be central to my own sporadic TDP-43 ALS.

Over the years, more and more pieces have fallen into place.

What began as a narrow hypothesis about one molecular mechanism gradually evolved into something broader - an energy balance hypothesis that may connect many apparently different forms of ALS under the same fundamental principle.

In short, I believe ALS is, at its core, starvation of the most energy-challenged cells in the human body.

That is why the disease appears to selectively target motor neurons. These cells operate extraordinarily close to their energetic limits even under normal conditions. They are large, metabolically expensive, constantly active, and uniquely dependent on maintaining long axons, ion gradients, intracellular transport, protein quality control, and synaptic function simultaneously over an entire lifetime.

The margin is razor-thin.

Different ALS variants appear to damage different parts of this balance. Some impair mitochondrial function. Some increase the energy cost of protein handling and autophagy. Some disrupt transport systems inside the neuron. Some alter RNA processing, stress granule behavior, or membrane excitability. Some increase the inflammatory burden. Others may reduce the efficiency of energy production itself.

But despite their differences, many of these pathways converge toward the same endpoint:

The neuron spends more energy than it can sustainably produce.

The exact route differs between genotypes, mutations, and sporadic disease forms, but the direction is strikingly similar. Each variant worsens the energy equation in its own way.

That may also explain why variant-indifferent ALS drug trials fail so consistently.

If ALS is not a single disease but many different mechanisms that collapse the same fragile energy balance, then treating all patients as a single, uniform population is almost guaranteed to dilute meaningful effects into statistical noise. A therapy helping one subtype may do little - or even cause harm - in another.

Frankly, the balance appears so delicate that it is almost a miracle we do not all get ALS.

Motor neurons survive for decades while operating under enormous energetic stress, continuously maintaining structures of extreme size and complexity without replacement. The system's resilience is extraordinary. But once the balance shifts too far - whether through genetics, aging, cumulative stress, metabolism, inflammation, or environmental factors - the system may no longer have enough margin left to compensate.

This book is not written from the perspective of a neurologist. I am an engineer who found himself confronting this disease against his own will. And now I'm about to focus on that one question:

What if ALS is fundamentally a problem of energy economics inside the most demanding cells in the human body?

Preface

I am not a doctor.
I have no formal medical education.
I never intended to study diseases at all.

I am simply someone who encountered this mystery against his own will.

But I am an engineer.

And engineers are trained to look at systems that fail.

To search for hidden constraints, feedback loops, bottlenecks, common factors, and conservation laws. To ask not only what breaks, but why it breaks there first. To look for patterns beneath seemingly unrelated symptoms.

ALS appears enormously complex. Genetics, protein aggregation, inflammation, excitotoxicity, mitochondrial dysfunction, transport defects, autophagy, RNA processing.

Yet complex systems often fail through surprisingly simple limits.

This text is not a claim of certainty.

It is an attempt to look at ALS not as isolated molecular fragments, but as a stressed energy system gradually losing its ability to sustain itself.

Acknowledgments

This book would not exist if I didn't exist. And I wouldn't exist without the contribution of many.

First of all, my daughter for giving me the reason to stay alive.

My wife for sacrificing much of her life for making that possible.

My friends and family for always giving a helping hand when needed. And it is needed a lot.

And, as always, Sonja Koistinen for encouraging me to write down my thoughts.

I have also had many good nurses, but I have no room to list them all, so I mention just one. Sofia. You always went the extra mile to make sure all is well. The world needs more people like you.

Prologue: On Quality of Life

One of the first things many newly diagnosed paralysis patients are taught is that their future life will not be worth living.

This is often not said with malice. It is presented as realism. The patient is warned about dependence, loss of mobility, inability to speak, inability to eat normally, and inability to breathe independently. Invasive ventilation is described as "prolonging life" rather than enabling it. Severe paralysis is framed less as a different form of existence and more as a gradual removal of humanity itself.

The message is clear enough: there comes a point where survival supposedly stops making sense.

The strange part is that these judgments are usually made by healthy people imagining paralysis from the outside.

A healthy person evaluates paralysis using the instincts of a healthy body. They imagine the horror of suddenly losing the ability to move while still carrying all the expectations, habits, and physical drives of normal life. Naturally, it appears unbearable.

But that is not how adaptation works. Human beings recalibrate.

The things that define daily existence change gradually as the disease progresses. Physical activity loses central importance. Energy conservation becomes instinctive. Small physical comforts become meaningful. Stability becomes valuable. The brain learns new routines, new priorities, new scales of effort, and new definitions of achievement.

Paralysis does not erase thought.

It does not erase personality, curiosity, humor, love, memory, intelligence, or the ability to contribute. A person may lose nearly all voluntary movement while remaining fully present internally. The body changes far more than the mind does.

The real danger comes from trying to preserve normality long after normality has become physiologically destructive.

Modern healthcare often assumes that maintaining normal routines automatically improves quality of life. Patients are encouraged to stay active, continue transfers, sit upright frequently, leave home regularly, participate in rehabilitation, and preserve the appearance of independence as long as possible.

For many severely paralyzed patients, this is not good care.

It is performance.

A failing neuromuscular system operates under brutally narrow energy margins. Activities that appear trivial to healthy people may consume enormous physiological reserves. Repeated transfers can exhaust respiratory muscles. Upright posture may worsen breathing mechanics. Travel may destabilize secretion management and sleep. Hygiene routines considered basic may involve substantial physical strain and medical risk.

Yet these burdens are often accepted unquestioningly because they resemble normal life.

The system rewards visible normality even when it quietly harms the patient.

A patient lying permanently in bed, communicating through eyegaze, minimizing physical activity, and structuring life entirely around respiratory stability is often viewed as having a poor quality of life. But from the patient's own perspective, such a life may instead feel stable, safe, intellectually active, and physically sustainable.

The problem is that medicine has remarkably few guidelines for optimizing long-term comfort and survival in profound paralysis.

Healthcare systems are historically organized around three goals:

- cure
- rehabilitation
- terminal care

There is much less institutional knowledge for patients who remain cognitively intact while living for decades in extreme physical dependency.

From the system perspective, this is understandable. Developing highly refined methods for maximizing long-term survival in severely disabled patients is expensive and resource-intensive. The number of patients is relatively small. Quiet acceptance of decline is simpler.

As a result, many patients and families develop their own survival culture outside formal medicine.

They learn respiratory care themselves. They discover through experience which activities worsen exhaustion and which improve stability. They abandon routines that look humane but feel destructive. They optimize positioning, ventilation, nutrition, secretion clearance, sleep, and energy use through years of trial and error.

Some of the most valuable practical knowledge in ALS is transmitted patient-to-patient rather than physician-to-patient.

The greatest misconception is the belief that dependence itself destroys dignity.

In reality, dependence is merely a technical condition.

A ventilator is equipment. A feeding tube is equipment. A hospital bed is equipment. None of these things reduces the value of a human being any more than eyeglasses or a wheelchair does. They are simply technologies compensating for failed biological functions.

The deeper problem is cultural.

Modern society treats independence as proof of human worth. Dependency is associated with failure, weakness, or loss of self. But severe paralysis exposes how fragile that assumption really is. Human value does not originate from muscle strength or physical autonomy. It originates from consciousness itself.

A person who cannot move may still think, create, teach, analyze, love, joke, argue, and participate in society.

The body becomes limited. The person does not disappear.

What many newly diagnosed patients truly need is not encouragement to preserve normality at all costs. They need permission to adapt completely.

To stop measuring life using standards designed for healthy bodies.

To stop performing health for the comfort of others.

To understand that survival with paralysis is not about winning a battle to remain normal. It is about constructing an entirely different equilibrium — one where comfort, stability, and meaning remain possible even when movement is gone.

1

Stress Granules

TDP-43 sits at the center of most ALS cases. Not only the inherited forms linked directly to TARDBP itself, but also the vast majority of so-called sporadic ALS. When pathologists open the spinal cord, they repeatedly find the same signature:

- TDP-43 is missing from the nucleus
- Abnormal TDP-43 aggregates in the cytoplasm
- Motor neurons are slowly dying

That pattern is so dominant that it is difficult to view it as a side phenomenon. It appears to be one of the disease's core failure modes.

Under normal conditions, TDP-43 is a highly dynamic nuclear protein. It binds RNA, regulates splicing, transport, stress responses, and helps determine which proteins the cell produces and when. Motor neurons depend heavily on this regulation because of their highly specialized geometry. Maintaining that structure demands continuous transport of RNA, proteins, vesicles, and mitochondria over enormous distances.

The energy demand is relentless.

And that is where stress granules come into play.

Stress granules are temporary assemblies that the cell forms under stress. When energy becomes limited, oxidative stress rises, or protein folding begins failing, the cell tries to protect itself by pausing nonessential protein translation. RNA and RNA-binding proteins condense into granules - temporary storage depots meant to buy time until conditions improve.

TDP-43 is one of the proteins recruited into these granules.

Normally, this is reversible.

The granules form, the stress passes, and the system returns to normal operation.

But TDP-43 contains prion-like low-complexity domains. These structures are useful because they enable rapid, flexible assembly into temporary liquid-like condensates. The same property, however, also creates danger. Under persistent stress, repeated cycling, mutation, aging, or impaired clearance, the liquid-like state may begin hardening into something more stable and pathological.

The granules stop behaving like dynamic droplets. They become aggregates.

At that point, two catastrophes occur simultaneously.

First, the toxic gain of function:

- aggregates physically disrupt the cytoplasm
- they trap RNA and other essential proteins
- they interfere with transport systems
- they burden autophagy and proteasomes
- they may spread templated misfolding to neighboring cells in a prion-like manner

The term “prion-like” does not mean ALS is contagious like classical prion disease. It means the abnormal folding state can seed further abnormal folding. Misfolded TDP-43 may encourage nearby normal TDP-43 molecules to adopt the same pathological structure, allowing pathology to propagate gradually through connected neural systems.

But the second catastrophe may be even more important: loss of nuclear function.

As TDP-43 becomes trapped in cytoplasmic inclusions, it disappears from the nucleus, where it is actually needed. The cell then loses critical RNA regulation functions:

- abnormal RNA splicing appears
- cryptic exons become activated
- protein production becomes disordered
- transport machinery degrades
- mitochondrial maintenance suffers
- stress handling weakens further

The neuron enters a vicious cycle.

Energy deficit promotes stress granule formation.

Stress granule pathology impairs cellular maintenance.

Maintenance failure worsens mitochondrial function and transport.

Energy production falls further.

More TDP-43 becomes trapped outside the nucleus.

Motor neurons may be uniquely vulnerable because they already operate near energetic limits. Their size alone creates extraordinary transport costs. Maintaining membrane potentials across huge axons consumes continuous ATP. Any impairment in mitochondrial efficiency, RNA regulation, axonal transport, or protein recycling pushes the system closer to collapse.

Different ALS genotypes may attack different sides of this balance.

Some impair protein clearance.

Some damage mitochondria directly.

Some increase oxidative stress.

Some destabilize RNA handling.

Some impair axonal transport.

Some directly alter stress granule dynamics.

But many may converge downstream onto the same final state: a neuron that can no longer maintain the energy required to preserve its own internal order.

And once TDP-43 pathology becomes self-sustaining, the disease may begin propagating through connected motor networks, almost like a slow systems-level cascade.

* * *

TDP-43 is often described as a protein aggregate in ALS, but its most important role is actually inside the cell nucleus. Under normal conditions, that is where TDP-43 belongs. The aggregates seen in diseased neurons are not just toxic junk. They are also evidence that the nucleus has lost one of its key regulatory proteins.

The nucleus is not merely a storage vault for DNA. It is an active control center where genes are continuously read, edited, and regulated. TDP-43 participates in that regulation at multiple levels. It binds RNA, controls splicing, suppresses cryptic exons, stabilizes transcripts, and regulates RNA export from the nucleus. In effect, it acts as part editor, part traffic controller, and part quality assurance system for gene expression.

One of the key functions of nuclear TDP-43 is suppression of cryptic exons. The genome contains many dormant sequence fragments that resemble exons but are not supposed to be included in mature RNA. TDP-43 keeps these hidden. When TDP-43 disappears from the nucleus, these cryptic sequences begin leaking into transcripts. The resulting RNAs are malformed and often destroyed before they can produce functional proteins.

This means that TDP-43 pathology is not simply about gain of toxicity from aggregates. It is also a catastrophic loss of nuclear function. The neuron suddenly starts producing defective instructions for itself.

Several genes critical for neuronal survival are affected. One example is STMN2, involved in axonal repair and maintenance. Loss of nuclear TDP-43 leads to abnormal processing of STMN2 RNA, effectively silencing an important repair system in the very cells that most need it. UNC13A is another important example. Certain genetic variants in UNC13A become particularly harmful only when TDP-43 function is lost, revealing how ALS genetics and TDP-43 pathology interact.

The process also appears self-amplifying. Cellular stress promotes the formation of stress granules in the cytoplasm. TDP-43 can become trapped there instead of returning to the nucleus. As nuclear depletion worsens, RNA processing deteriorates further, creating additional stress and energy burden on the cell. Eventually, the neuron enters a downward spiral where both nuclear regulation and cytoplasmic protein handling fail simultaneously.

From an engineering perspective, the nucleus loses part of its error-correction system. The neuron can tolerate some damage for years, perhaps decades, but eventually the accumulation of transcriptional and metabolic errors exceeds the cell's capacity to compensate. The visible TDP-43 inclusions may therefore be less important than the invisible absence of TDP-43 from where it was actually needed.

* * *

Stress granules are meant to be temporary shelters, not permanent housing.

When a cell is under stress, it pauses part of its protein production and packs selected RNA and RNA-binding proteins into stress granules. That is not automatically bad. It is a survival response. The cell is trying to conserve energy, reduce translation load, and protect vulnerable messenger RNAs until conditions improve.

The problem begins when the emergency mode does not switch off.

In ALS, especially in TDP-43- and FUS-related disease biology, stress granules are of interest because they sit at the boundary between normal adaptation and pathological aggregation. TDP-43 is normally a nuclear RNA-handling protein. Under stress, some of it can move into the cytoplasm and associate with stress granules. If stress is brief, the granules dissolve, proteins return to useful work, and the cell recovers. If stress is chronic, energy is low, autophagy is weak, oxidative damage is high, and the same granules may become seeds for something more permanent.

That is where "promoting stress granule breakup" becomes attractive.

The goal is not to abolish the stress response. That would be stupid. A neuron under stress needs ways to pause, triage, and protect itself. The goal is to prevent temporary liquid-like droplets from aging into sticky, solid, toxic junk. In engineering terms, the problem is not that the system has an emergency mode. The problem is that it gets stuck there, and the emergency configuration slowly becomes the failure configuration.

Breaking up stress granules could help in several ways.

First, it may return trapped RNA and proteins back to normal circulation. A motor neuron cannot afford to have important RNA-processing machinery parked indefinitely in cytoplasmic blobs. It already has ridiculous geometry. Its logistics are bad even on a good day. Sequestering key RNA-binding proteins only makes the supply chain worse.

Second, it may reduce the likelihood that TDP-43, FUS, and similar proteins cross the threshold from reversible assembly to irreversible aggregation. Many of these proteins contain low-complexity domains, which are useful for forming dynamic condensates but also make them prone to pathological phase transitions. That is a clever material property until the solvent chemistry, ATP level, chaperone capacity, and cleanup systems all deteriorate. Then clever becomes dangerous.

Third, it may reduce the burden on autophagy and proteasomal cleanup. A cell with a good energy supply can tolerate mess. A cell with a poor energy supply must avoid making a mess in the first place. Waiting for large aggregates to form, then asking a damaged neuron to clean them up, is like letting sludge accumulate in a cooling system and then blaming the pump for failing.

So the sensible strategy is upstream: keep stress granules dynamic, reversible, and short-lived.

In practice, this points toward several biological levers. Improve cellular energy status. Reduce oxidative and inflammatory stress. Support chaperone function. Maintain autophagy. Avoid hypoxia. Avoid unnecessary physical strain. Avoid chronic excitotoxic load. None of this is magic, and none should be sold as a cure. But the logic is coherent: a neuron that is less stressed has less reason to form persistent granules, and a neuron with better energy and cleanup capacity is more likely to dissolve them before they harden into pathology.

The hard part is that stress granules are not simply garbage. They are part of normal cell biology. Push too hard, and you may damage a protective response. Push too little, and chronic stress turns the response into a disease amplifier.

That is why ALS research should not only ask how aggregates are removed after they appear. It should also ask why reversible RNA granules fail to reverse. The interesting therapeutic target may not be the final graveyard of aggregated protein, but the earlier moment when a stressed neuron still has a choice: recover, dissolve the granule, restore RNA handling, or remain stuck in emergency mode until adaptation becomes pathology.

2

Chaperones

Protein chaperones are the cellular maintenance crews that try to keep the proteome from collapsing into chaos.

Every protein in the body must fold into a very precise three-dimensional shape before it can function. That sounds trivial until you realize what the cell is actually attempting: long chains of amino acids are synthesized in a crowded, hot, chemically aggressive environment where thousands of molecules constantly collide with each other. Left alone, many proteins would simply stick together into useless clumps.

Chaperones exist to prevent that.

They bind partially folded or damaged proteins, shield sticky regions, help proteins fold correctly, refold stress-damaged structures, escort proteins across membranes, and sometimes deliver hopelessly damaged proteins for destruction. In a sense, they are the quality control system that keeps life chemically possible.

The most famous family is heat shock proteins (HSPs). The name comes from the observation that cells massively increase chaperone production during heat stress, because elevated temperature destabilizes proteins and causes misfolding. But heat is only one threat. Oxidative stress, hypoxia, inflammation, energy failure, toxins, mutations, and aging all increase the burden.

ALS is essentially a disease where this burden gradually exceeds the system's ability to cope. When protein maintenance begins to fail, the consequences accumulate slowly for years before symptoms appear.

TDP-43 aggregation is one example of this collapse. Under stress, TDP-43 can become trapped in stress granules and misfold. Chaperones attempt to rescue and refold these proteins, but if the stress persists long enough, aggregates become increasingly stable and difficult to clear. Eventually, the cleanup machinery itself becomes overloaded.

At that point, the cell enters a vicious cycle.

Misfolded proteins consume chaperone capacity. Reduced chaperone availability allows even more proteins to misfold. Aggregates impair mitochondria and transport systems, reducing ATP production. But chaperones themselves require energy to function properly. So declining energy production weakens the very systems needed to prevent further protein collapse.

The cell slowly loses control of its internal chemistry.

This is why many apparently unrelated ALS pathways begin converging toward the same endpoint. SOD1 mutations, C9orf72 repeat expansions, oxidative stress, impaired autophagy, mitochondrial dysfunction, axonal transport failure, and excitotoxicity — all of them increase the burden on protein maintenance systems in one way or another.

For decades, medicine has often described protein aggregates mainly as toxic debris. But increasingly, they look more like evidence that the maintenance system has become saturated. The aggregates are not necessarily the original cause. They may simply mark the point where the cell can no longer keep damaged proteins soluble and functional.

From an engineering perspective, chaperones resemble an overloaded maintenance department in an aging industrial plant.

As long as spare capacity exists, disturbances remain manageable. Pumps fail, valves stick, sensors drift, but the maintenance crews compensate. Eventually, however, too many systems begin degrading simultaneously. Maintenance becomes reactive instead of preventive. Small failures start coupling together. Then the plant enters a regime where deterioration accelerates faster than repairs can keep up.

That transition may be what neurodegeneration really is.

This also explains why therapies aimed purely at removing aggregates often disappoint. Dissolving visible protein clumps does not automatically restore the underlying maintenance capacity that failed in the first place. If the cell still suffers from energy shortage, oxidative stress, transport dysfunction, or impaired proteostasis, new aggregates simply form again.

The real challenge may not be removing damaged proteins, but restoring enough cellular energy and a quality-control reserve margin so the system regains control.

* * *

If chaperones are the maintenance crews of the cell, helping them mostly means reducing the workload and ensuring they still have enough energy and raw materials to function.

Unfortunately, modern medicine often approaches neurodegeneration backward. It searches for a magical molecule that directly removes aggregates, while paying surprisingly little attention to the cell's overall operating conditions. But chaperones do not work in isolation. Their performance depends heavily on cellular energy state, oxidative stress level, temperature, inflammation, and protein turnover burden.

The first priority is therefore energy preservation.

Protein refolding is ATP-intensive work. A stressed neuron already struggles to maintain membrane potentials, axonal transport, calcium gradients, vesicle recycling, and mitochondrial repair. If the entire organism is additionally pushed into exhaustion, sleep deprivation, respiratory strain, or chronic stress, less energy remains available for protein maintenance.

This is one reason excessive physical strain may be harmful in ALS. Exercise is healthy when reserve capacity exists. But once motor neurons are already operating near failure margins, constant overloading may simply accelerate protein damage and oxidative stress faster than repair systems can compensate.

Good ventilation probably matters more than many realize.

Hypoxia destabilizes proteins, impairs mitochondria, increases oxidative stress, and reduces ATP production simultaneously. Chaperones can only function if there is enough energy to run them. Chronic mild respiratory insufficiency may therefore quietly worsen proteostasis failure long before dramatic symptoms appear. From this perspective, ventilatory support is not merely about comfort or blood gases. It may directly reduce cellular stress.

Sleep is another underestimated factor. Much of the cell's repair and cleanup activity is shifted toward rest periods. Chronic fragmented sleep means maintenance crews never fully catch up.

Heat avoidance may also matter. Chaperones are called heat shock proteins for a reason. Elevated temperature increases protein instability and the tendency to aggregate. Many ALS patients intuitively avoid overheating long before understanding the biology behind it.

Nutrition matters less through miracle compounds and more through maintaining the entire maintenance economy of the cell.

Adequate calories are critical because a catabolic state forces the body to resort to self-cannibalism and stress signaling. Weight loss in ALS is consistently associated with worse outcomes. The body simply lacks enough reserve to sustain continuous repair operations.

Some supplements are biologically plausible because they support systems closely tied to proteostasis:

- NAC may support glutathione production and reduce oxidative stress burden
- creatine may help buffer cellular energy availability
- CoQ10 participates in mitochondrial electron transport
- curcumin may modestly reduce inflammatory signaling
- TUDCA may help ER stress handling and protein folding pathways
- nicotinamide riboside may support NAD^+ metabolism and mitochondrial maintenance

None are proven cures. But all target systems that interact directly with the chaperone workload and cellular maintenance capacity.

Reducing inflammation may help as well. Inflammatory signaling shifts cells into defensive modes that increase oxidative burden and disrupt normal protein handling. Chronic neuroinflammation effectively keeps the maintenance crews working emergency overtime indefinitely.

And finally, avoiding unnecessary stress on the nervous system itself matters.

Constant fear, panic, sleep deprivation, endless doomscrolling about prognosis, and psychological overload are not abstract emotional issues. Stress hormones alter metabolism, inflammation, mitochondrial function, and protein turnover. The brain is still biology. A neuron under continuous stress operates under worse chemical conditions than one allowed relative stability.

None of this means ALS can currently be stopped simply by "living correctly." The disease is far more complex than that. But from a systems perspective, nearly everything associated with slower progression tends to reduce overall cellular stress and preserve maintenance reserve margin.

That is exactly what one would expect if neurodegeneration is, at least partly, a failure of long-term cellular maintenance capacity.

3

Axonal Transport

A motor neuron is not merely a cell. It is a cell attached to an absurdly long logistics chain.

The neuron body may sit in the spinal cord while the axon extends over a meter to reach a muscle. Everything needed at the far end must be transported there continuously:

- mitochondria
- proteins
- vesicles
- repair machinery
- structural components
- signaling molecules

At the same time, waste and damage signals must be transported back toward the nucleus.

This is called axonal transport.

The process depends on molecular motors walking along microtubule tracks inside the axon. Kinesins generally move cargo outward toward the muscle. Dyneins move cargo back inward toward the cell body. The entire system consumes large amounts of ATP.

When energy production weakens, transport begins to fail. And transport failure itself then worsens the energy problem.

Mitochondria no longer reach distant parts of the axon efficiently. Local ATP production falls. Calcium buffering worsens. Synapses begin malfunctioning. Cleanup systems fail to receive supplies. Debris accumulates. Microtubules destabilize. Traffic jams form inside the axon.

The neuron enters a vicious cycle.

This may also help explain why motor neurons are selectively vulnerable in ALS. Many other cells can tolerate partial transport impairment because their geometry is compact. Motor neurons cannot. Their architecture leaves very little reserve margin.

The situation is like maintaining a remote railway amid a collapsing supply network. If fuel deliveries weaken, maintenance crews cannot reach damaged sections. Tracks degrade further. Transport slows more. Eventually, entire regions become unreachable.

TDP-43 pathology may worsen this further. TDP-43 regulates many RNAs involved in cytoskeletal stability, stress responses, and transport machinery. When TDP-43 is lost from the nucleus, the neuron gradually loses the ability to maintain its internal infrastructure.

Some ALS-associated mutations appear directly linked to transport problems. Others impair mitochondria, protein handling, or autophagy, but the result converges toward the same endpoint: axonal logistics failure.

From an energy perspective, ALS can be viewed as a disease in which neurons become unable to sustain their energy supply.

* * *

There is currently no proven way to directly restore failing axonal transport in ALS. If there were, it would likely dramatically slow the disease. But several approaches are at least biologically plausible because they reduce the load placed on the transport system or support the conditions it depends on.

The first principle is energy preservation.

Axonal transport runs on ATP. Every unnecessary physical strain, infection, hypoxia episode, sleep disruption, or respiratory burden steals energy from cellular maintenance. In ALS, the reserve margin is already tiny. Once transport begins to fail, the neuron loses its ability to repair itself.

This is why respiratory support matters far beyond comfort. Good ventilation reduces hypoxia, CO_2 stress, inflammatory signaling, and the work of breathing. A ventilator is not merely helping the lungs. It may also indirectly reduce metabolic load on neurons.

Avoiding weight loss is also important. ALS patients often become hypermetabolic. Starvation forces the body into a chronic energy deficit, exactly when neurons need a stable supply of fuel. The old cultural instinct that illness should make one “eat lightly” is probably harmful here.

Inflammation reduction may help indirectly as well. Chronic inflammation increases oxidative stress and the cleanup burden inside neurons. Even mild infections can temporarily worsen function. That does not prove that neurons are dying during every setback, but it shows how little reserve there is.

Sleep quality matters for similar reasons. Deep sleep is when much of the brain’s maintenance and waste clearance occurs. Fragmented sleep, hypoventilation, or repeated nocturnal desaturations may quietly increase stress on already vulnerable neurons.

Avoiding overexertion is probably more important than any supplement.

Healthy people improve by stressing tissues beyond their current capacity and recovering stronger. ALS neurons may not tolerate that logic. Heavy exertion increases oxidative stress, glutamate signaling, calcium influx, and transport demand. A damaged logistics system may simply fall further behind afterward.

That does not mean complete inactivity is ideal. It means the goal shifts from maximizing performance to preserving stability.

In the end, helping axonal transport probably means helping the entire cellular economy around it:

- sufficient energy
- sufficient oxygenation
- stable sleep
- reduced inflammation
- reduced metabolic stress
- minimized infections
- adequate nutrition
- avoiding excessive strain

None of this fixes the underlying disease. But if ALS progression partly reflects neurons losing the ability to maintain their own internal supply chains, then reducing the load on those supply chains is at least rational.

4

The Energy Hypothesis

ALS is usually described in terms of what dies.

Motor neurons degenerate. Muscles weaken. Proteins aggregate. Axons retract. Eventually, the system fails.

But that framing may describe the endpoint more clearly than the mechanism.

There is another possibility: that many forms of ALS are, at their core, diseases of energy management inside an exceptionally demanding biological system.

A motor neuron is not an ordinary cell. It is enormous, electrically active, structurally extended over long distances, and expected to function continuously for decades without replacement. The margin may already be narrow under normal conditions.

If that margin erodes - slowly, chronically, perhaps differently in different ALS subtypes - the first systems to fail are likely not random. They are the most energy-intensive and least tolerant of interruption.

This perspective potentially connects observations that otherwise appear unrelated:

- hypermetabolism seen in many ALS patients
- the strong association between low BMI and worse prognosis
- mitochondrial abnormalities
- impaired axonal transport
- glutamate excitotoxicity
- altered lipid metabolism
- autophagy dysfunction
- TDP-43 pathology
- stress granule persistence
- selective vulnerability of motor neurons

These may not all be primary causes. Some may instead be downstream manifestations of a cell operating in a prolonged energetic deficit.

In that view, protein aggregation is not necessarily the origin of the disease. It may partly reflect a system that can no longer afford proper maintenance. Cellular cleanup itself consumes energy. Repair consumes energy. Adaptation consumes energy. Even protective responses may become self-destructive if they increase metabolic demand faster than ATP production can sustain.

The hypothesis does not claim that all ALS cases have a single cause. ALS is likely a family of diseases. But different initiating defects may still converge toward a shared failure mode: collapse of energy balance inside highly specialized neurons with little reserve capacity.

That possibility matters because it changes the question.

Instead of asking only:
“What toxic process kills the neuron?”

we may also need to ask:
“What happens when the neuron can no longer afford to remain alive?”

* * *

One of the strongest arguments supporting an energy-based view of ALS is that the disease usually begins late in life.

If the primary problem were simply a toxic mutation or a single catastrophic trigger, one would expect many cases to appear much earlier. Yet most motor neurons survive for decades before failure begins. Something changes slowly over time until the system can no longer maintain stability.

That resembles exhaustion of reserve capacity more than sudden poisoning.

Youth hides inefficiency well. Aging does not.

With age, mitochondrial performance slowly declines, oxidative damage accumulates, protein recycling becomes less efficient, autophagy slows, vascular reserve worsens, sleep quality deteriorates, and chronic inflammation increases. None of these changes alone necessarily kills neurons. But together they reduce the safety margins of a cell type that already operates near the edge.

The late onset of ALS, therefore, fits well with the idea that motor neurons are failing because the long-term energy and maintenance economy finally collapses below a critical threshold.

That may also explain why the disease often accelerates after onset. Once axonal transport weakens, mitochondria fail to reach distal regions efficiently. Synapses begin malfunctioning. A denervated muscle further increases metabolic stress. Inflammation rises. Protein aggregates accumulate faster. The neuron then spends more energy trying to compensate precisely as its energy production capacity declines.

The system enters a positive feedback loop.

This perspective also explains why aging itself is the single largest risk factor for many neurodegenerative diseases, not just ALS. Different neuron populations fail first depending on genetics and vulnerability, but the underlying theme may be similar: extremely specialized, long-lived cells eventually lose the energetic ability to maintain themselves indefinitely.

From this viewpoint, ALS may not be a disease in which neurons are suddenly attacked out of the blue. It may instead be a disease in which the most metabolically demanding cells in the body gradually lose the ability to meet maintenance requirements accumulated over a lifetime.

* * *

ALS variants often appear very different on the surface.

Different genes. Different protein aggregates. Different progression rates. Different ages of onset.

But many of them can also be interpreted through a common systems-level lens: the balance between cellular energy supply and energy demand.

The mechanisms differ, but the result repeatedly points toward the same problem — motor neurons operating with insufficient metabolic margin.

Some variants appear to directly reduce energy production.

- mitochondrial dysfunction lowers ATP generation
- oxidative stress damages energy-producing machinery
- impaired glucose utilization may reduce substrate availability
- defects in mitochondrial transport prevent energy delivery to distant axonal regions

Others appear to increase energy consumption.

- hyperexcitability increases ion-pumping demand

- chronic stress responses consume ATP continuously
- protein misfolding increases chaperone and degradation workload
- axonal repair and inflammatory signaling raise baseline metabolic load

Some variants may do both simultaneously. TDP-43 pathology is a possible example.

Mislocalized TDP-43 disrupts RNA processing and cellular organization, but also appears tightly linked to impaired autophagy and abnormal protein clearance. Autophagy is not free. It is an energy-consuming survival mechanism. A chronically stressed neuron may begin consuming large amounts of ATP simply trying to maintain internal order and remove damaged components.

The cell enters a vicious cycle:

- stress increases cleanup demand
- cleanup consumes energy
- lower energy impairs cleanup efficiency
- damaged components accumulate further
- stress rises again

SOD1-linked disease may involve oxidative damage to mitochondria and intracellular transport systems. C9orf72 variants may combine RNA toxicity, abnormal peptide production, impaired trafficking, and defective autophagic regulation. FUS mutations disrupt RNA handling and stress granule dynamics, thereby increasing the cellular maintenance burden.

The details differ.

But many pathways appear to converge on the same systems-level outcome: the neuron spends more energy while simultaneously becoming less able to produce or distribute it.

Motor neurons are uniquely vulnerable to this because they already operate near energetic limits. A small efficiency loss that would be irrelevant in another cell type may become fatal in a motor neuron sustained over years.

This framework may also explain several observations surrounding ALS:

- lower BMI is often associated with worse prognosis
- hypermetabolism is common in many patients
- energy-dense nutrition sometimes appears beneficial
- physical overexertion may accelerate progression in susceptible individuals
- mitochondrial and metabolic drugs repeatedly emerge as partial therapeutic candidates even when targeting different upstream mechanisms

None of this necessarily means energy imbalance is the original cause of every ALS subtype.

But it may be the common bottleneck through which many otherwise unrelated pathologies ultimately kill the neuron.

Different roads.

Same cliff edge.

5

Excitotoxicity

Excitotoxicity is usually described as neurons being "over-stimulated" by glutamate. That is true, but from an energy perspective, the real problem is what happens afterward.

Every nerve impulse depends on ion gradients across the cell membrane. Sodium is kept outside the cell, potassium inside, and calcium at extremely low concentrations inside. Maintaining those gradients is enormously expensive. The neuron is constantly spending ATP to pump ions back where they belong.

Excitotoxicity pushes this system beyond its limits.

When excess glutamate accumulates around synapses, glutamate receptors remain open too long. Sodium and especially calcium flood into the neuron. The cell immediately tries to restore order by pumping the ions back out. That massively increases ATP demand at exactly the time when the system is already stressed.

Calcium is particularly dangerous because it does not merely disturb membrane voltage. It activates enzymes, alters signaling pathways, damages mitochondria, and increases production of reactive oxygen species. The mitochondria then produce less ATP precisely when the neuron needs more.

The cell enters an uncontrollable tailspin.

Low energy impairs ion pumping. Impaired ion pumping depolarizes the membrane. Depolarization increases glutamate release and receptor activation. More calcium enters. Mitochondria become more damaged. Energy production falls further.

At some point, the neuron can no longer maintain separation between inside and outside. Electrical stability collapses. The cell enters a state of persistent metabolic emergency from which it may never recover.

From this perspective, excitotoxicity is not simply "too much signaling." It is an energy crisis triggered by excessive signaling.

This also explains why excitotoxicity alone probably does not fully explain ALS. Healthy neurons tolerate glutamate surges surprisingly well. The real danger appears when excitotoxicity is layered on top of preexisting energetic weakness:

- impaired mitochondria
- defective protein cleanup
- disrupted axonal transport
- chronic inflammation
- oxidative stress

- aging
- impaired blood supply
- defective RNA handling, such as TDP-43 pathology

Each factor reduces the safety margin slightly. Excitotoxicity then becomes the event that pushes the system over the edge.

In that sense, glutamate may not be the root cause. It may simply be the final load applied to an already collapsing electrical grid.

* * *

From an energy perspective, reducing excitotoxicity means reducing unnecessary neuronal workload and preserving ATP production. In ALS, that probably matters more than trying to block glutamate directly.

One obvious target is physical overexertion. Motor neurons fire continuously during movement, and every impulse costs energy. A healthy system tolerates that easily. An already energy-starved motor neuron may not. Many ALS patients eventually discover that aggressive exercise leaves prolonged worsening afterward. The system simply lacks reserve.

Stress and sleep deprivation likely matter for similar reasons. Cortical activity, muscle tone, sympathetic activation, and poor sleep all increase metabolic demand. Even thinking intensely for long periods may become exhausting because the diseased nervous system is already operating close to failure.

Respiratory support is probably one of the most effective anti-excitotoxic interventions available today. Breathing is a continuous motor neuron activity. When respiratory muscles weaken, the body compensates with enormous effort. Mechanical ventilation removes that workload. It also improves oxygen delivery and sleep quality, both of which are critical for mitochondrial energy production.

Good nutrition matters because neurons cannot store meaningful energy reserves. Weight loss in ALS is a bad sign, partly because it reflects negative energy balance. Many patients survive longer when they intentionally maintain or even increase their weight.

Inflammation reduction may also help indirectly. Activated microglia and astrocytes can worsen glutamate toxicity and oxidative stress. This is one reason why infections are so dangerous in ALS - they sharply increase systemic and neuronal energy demand at the same time.

Several supplements are popular because they plausibly support mitochondrial function or reduce oxidative stress, even if proof remains limited. CoQ10, acetyl-L-carnitine, curcumin, NAC, creatine, TUDCA, and nicotinamide riboside all fit somewhere into that framework. None is a miracle treatment. The idea is merely to slightly improve the energy balance or reduce collateral damage.

Direct anti-excitotoxic drugs have mostly disappointed. Riluzole probably works partly through reducing glutamatergic activity, but the benefit is modest. That may be because excitotoxicity is downstream of a broader metabolic failure rather than the primary disease itself.

The uncomfortable implication is that ALS management often resembles energy rationing more than aggressive rehabilitation. Preserve function. Avoid metabolic crises. Avoid infections. Avoid exhaustion. Keep breathing effortless. Keep nutrition high. Reduce unnecessary load on already struggling neurons.

A failing power grid is stabilized not by demanding more from it, but by reducing load while supporting generation.

6

Hypoxia

Hypoxia is not simply “lack of oxygen.” It is a failure of energy production.

Cells continuously consume oxygen in mitochondria to produce ATP. ATP is what maintains ion gradients, powers transport systems, recycles proteins, repairs membranes, and ultimately keeps the cell alive. When oxygen delivery drops, ATP production falls almost immediately. The cell then begins shutting down functions in order of importance.

The brain and motor neurons are particularly vulnerable because their baseline energy consumption is enormous.

Early hypoxia often looks deceptively mild. The cell compensates:

- glycolysis increases
- lactate production rises
- unnecessary activity is reduced

- ion pumps begin operating closer to their limits

But compensation itself has a cost. Acidosis develops. Calcium handling deteriorates. Glutamate clearance weakens. Oxidative stress rises when damaged mitochondria begin leaking reactive oxygen species.

Eventually, the system enters a downward spiral.

Low ATP weakens ion pumping. Sodium and calcium accumulate inside the cell. Membrane potentials destabilize. Excitotoxic signaling increases. Excitotoxicity then increases ATP demand further because the cell must pump those ions back out. The energy deficit worsens precisely when more energy is needed.

That is why severe hypoxia causes neurons to die rapidly.

The dangerous part is that hypoxia is often not absolute. Cells do not need complete oxygen deprivation to suffer. Chronic mild hypoxia may be enough to slowly push vulnerable cells over the edge, especially if they already carry another burden.

In those conditions, the energy margin may already be nearly exhausted. Oxygen shortage then becomes the final destabilizing factor rather than the primary cause.

Hypoxia also explains why the body prioritizes certain functions during respiratory failure. Cognitive slowing, fatigue, poor concentration, and muscle weakness appear before total collapse because the system is attempting controlled energy rationing.

The body sacrifices performance to preserve survival.

Long-term ventilation support in diseases like Amyotrophic Lateral Sclerosis is therefore not merely "breathing assistance." It is the maintenance of the cellular energy supply. Adequate oxygenation and CO_2 removal reduce the metabolic stress placed on already energy-starved neurons and respiratory muscles.

Carbon dioxide matters as much as oxygen. Rising CO_2 levels cause acidosis, increase respiratory drive, disrupt sleep quality, worsen fatigue, and further increase systemic stress. Many patients tolerate declining oxygen surprisingly long, while hypercapnia quietly destroys function and reserves.

From an engineering perspective, hypoxia is like operating a power grid below its required generation capacity. At first, nonessential loads are shed. Voltage stability deteriorates. Protective margins disappear. Small disturbances that were previously harmless now trigger cascading failures. Eventually, even core stabilization systems fail because the energy needed to maintain order no longer exists.

* * *

Avoiding hypoxia in ALS is mostly about reducing respiratory workload before the system reaches crisis.

The first step is recognizing that shortness of breath is often a late symptom. Long before obvious respiratory failure appears, the body may already be compensating with enormous effort. Fatigue, poor sleep, morning headaches, sweating, nightmares, anxiety at night, difficulty speaking long sentences, and daytime sleepiness may all reflect chronic underventilation.

Ventilatory support should ideally begin before repeated hypoxic episodes occur. Noninvasive ventilation during sleep can dramatically reduce nightly respiratory stress. Once the respiratory muscles weaken further, invasive ventilation removes even more of the continuous workload from the system.

Secretion control is equally important. Oxygen cannot reach the bloodstream efficiently if the lungs are partially blocked with mucus. Cough assist is therefore not an optional comfort device. It is one of the primary tools for preventing pneumonia and maintaining oxygen transfer.

Hydration matters because dehydrated secretions become thick and difficult to clear. NAC may help by reducing mucus viscosity. Dry indoor air can worsen secretory problems.

Avoiding infections is critical. A mild respiratory infection for a healthy person may become catastrophic in ALS because it simultaneously increases oxygen demand and impairs oxygen delivery. Visitors with respiratory symptoms should simply stay away. Survival sometimes depends on being willing to appear "overprotective."

Overexertion should also be avoided. In ALS, exhaustion itself can provoke hypoventilation. A healthy person compensates automatically by breathing harder. Weak respiratory muscles may no longer be able to maintain that reserve. Even showering, transfers, prolonged upright positioning, or emotional stress may consume surprisingly large amounts of respiratory capacity.

Sleep positioning matters. Many patients breathe worse lying flat because abdominal contents push against the diaphragm. Slight elevation or carefully optimized bed positioning may reduce respiratory effort considerably.

Monitoring carbon dioxide is often more informative than monitoring oxygen alone. Oxygen saturation may remain deceptively normal until very late, especially with supplemental oxygen. Meanwhile, carbon dioxide rises gradually, increasing fatigue and stressing the nervous system.

Supplemental oxygen alone can even be dangerous in neuromuscular respiratory failure if ventilation itself is inadequate. The real problem is often insufficient removal of CO_2 rather than a lack of oxygen entering the lungs.

From an energy perspective, the goal is not athletic performance or "pushing through." The goal is to maintain stable oxygen delivery with the smallest possible metabolic cost.

A failing system survives by reducing load, avoiding spikes, and preventing cascading failures before they begin.

* * *

Many ALS patients on invasive ventilation eventually notice something curious. They often feel better when the ventilator provides slightly more ventilation than strictly necessary. Sleep improves, thinking becomes clearer, and the constant sensation of respiratory strain fades. This naturally raises the question: could slight hyperventilation actually be beneficial?

From an energy perspective, the idea makes sense.

Breathing is not free. Respiratory muscles consume energy continuously, every second of every day. In healthy people, this workload is small enough to go unnoticed. In ALS, it gradually becomes a major metabolic burden. The body may expend enormous effort simply to move air in and out.

Invasive ventilation changes that equation completely. The ventilator takes over most or all of the mechanical work of breathing. Oxygen delivery improves, carbon dioxide removal stabilizes, and the respiratory muscles finally stop fighting a losing battle.

If ventilation is increased slightly further, carbon dioxide levels decrease somewhat below the patient's spontaneous baseline. Many patients describe this as feeling "lighter" or more comfortable. There are several possible reasons.

Lower CO_2 reduces respiratory drive. The brain no longer feels an urgent need to breathe harder. Air hunger decreases. Sleep fragmentation may improve. The nervous system operates in a calmer state because one of its largest continuous stressors has been removed.

Slight hyperventilation may also create reserve capacity. If secretions temporarily obstruct airflow, or positioning worsens ventilation during sleep, carbon dioxide has farther to rise before reaching dangerous levels. The system gains margin.

From an ALS standpoint, margin matters enormously. Motor neurons already operate close to energetic collapse. Anything that reduces continuous metabolic load may help stabilize the system.

However, more ventilation is not automatically better.

Carbon dioxide is not merely a waste product. It is a tightly regulated component of physiology. Excessive hyperventilation lowers CO_2 too far, causing cerebral blood vessels to constrict. Brain blood flow decreases. Respiratory alkalosis develops. Secretions may dry and become harder to clear. Sleep quality can paradoxically worsen despite excellent gas-exchange values.

Low CO_2 may also increase neuronal excitability. That is potentially undesirable in a disease already associated with excitotoxic stress and unstable neuronal energy balance.

There is another important issue: comfort. ALS patients often become highly sensitive to ventilator settings. Excessively aggressive ventilation can produce an unpleasant sensation of being “overventilated.” Synchronization with the ventilator may worsen. Swallowed air increases. The patient may feel restless rather than relaxed.

This illustrates a broader problem in medicine. Ventilator management is often guided by blood gas targets and textbook normal values. But ALS is not simply a gas exchange problem.

It is an energy management problem.

The ideal ventilator strategy is therefore probably not maximal ventilation. It is a minimal physiological strain.

That usually means:

- stable oxygenation
- near effortless breathing
- good secretion clearance
- restful sleep
- comfortable synchronization with the ventilator
- carbon dioxide levels normal or only mildly reduced

The objective is not to produce perfect laboratory numbers. It is to reduce the total energetic burden placed on an already failing nervous system.

From that perspective, slight hyperventilation may indeed be beneficial for some ALS patients. Not because low CO_2 itself is therapeutic, but because reducing respiratory stress helps stabilize the body's overall energy balance.

A failing electrical grid survives not by operating at maximum output, but by reducing continuous load and preserving reserve capacity. ALS may not be very different.

7

SOD1 ALS

Superoxide dismutase 1 is an enzyme whose job is to protect cells from superoxide radicals produced during normal metabolism.

Superoxide is oxygen that has picked up an extra electron:

O_2^-

That extra electron makes the molecule unstable and highly reactive. Left uncontrolled, it damages proteins, membranes, DNA, and mitochondria.

SOD1 neutralizes superoxide through the reaction:

$2\ O_2^- + 2\ H^+ \rightarrow H_2O_2 + O_2$

The resulting hydrogen peroxide can then be further broken down by other cellular defense systems.

For a long time, SOD1 ALS was thought to be mainly a disease of failed antioxidant protection. That turned out to be incomplete. Most SOD1 mutations do not simply remove enzyme activity. Many mutant forms still work at least partially. The real problem is that the protein itself becomes unstable.

The mutant SOD1 protein misfolds.

Once misfolded, it begins to stick to itself and to other cellular structures. Aggregates form, mitochondria become damaged, axonal transport slows, protein degradation systems become overloaded, and cellular stress responses remain continuously active. The motor neuron is forced into an endless maintenance battle that consumes more and more energy merely to stay alive.

That is why SOD1 ALS fits the energy-balance hypothesis so well.

The disease is not merely oxidative stress. It is an energy crisis driven by chronic cellular damage and a cleanup burden. The neuron must continuously spend ATP to refold or degrade damaged proteins, isolate aggregates, repair mitochondria, maintain ion gradients, sustain axonal transport across enormous distances, and contain ongoing oxidative damage. But the same mitochondrial dysfunction that increases energy demand also reduces the cell's ability to produce energy.

The system therefore spirals in the wrong direction.

Motor neurons fail first because they already operate near the edge. They are the largest and most energy-demanding cells in the body. They cannot simply divide and replace themselves. Once a motor neuron dies, the pathway it formed during embryonic development is effectively impossible to reconstruct.

Different ALS variants may begin through different mechanisms, but many appear to converge downstream on the same fundamental problem: the motor neuron can no longer maintain its energy balance.

SOD1 simply makes that collapse unusually visible.

* * *

SOD1 ALS is one of the cleanest examples of ALS as a failure of cellular housekeeping.

The mutation does not simply remove a useful enzyme. It confers a toxic new behavior on the SOD1 protein. It misfolds, aggregates, interferes with mitochondria, increases oxidative stress, disturbs calcium handling, burdens proteostasis, and turns the motor neuron into a cell that must spend more and more energy merely to remain alive. Mitochondrial dysfunction is an early and central feature in mutant SOD1 models.

In that sense, SOD1 ALS fits the energy-balance hypothesis almost too well.

The mutant protein creates a constant internal maintenance crisis. The cell must fold, refold, degrade, transport, buffer, repair, and detoxify. Each task consumes ATP. Each failed task creates more damage. Damaged mitochondria then produce less usable energy and more reactive stress. The result is a vicious circle: the cell needs more energy because it is damaged, but it has less because the damage has reached the machinery that generates energy.

This is why SOD1 ALS is not merely "oxidative stress." That phrase is too small. Oxidative stress is one visible flame. The fire is system-level failure: protein quality control, mitochondrial function, axonal transport, glial support, inflammation, and energy metabolism all pulling in the wrong direction at once.

Tofersen is important because it targets one of the rare ALS forms in which the upstream driver is known. It reduces SOD1 production by targeting SOD1 mRNA, and FDA accelerated approval was based on reduced CSF SOD1 and neurofilament light chain, a marker of neuronal injury. Europe granted marketing authorization for Qalsody in 2024 under exceptional circumstances for SOD1 ALS.

But even there, the lesson is broader than one gene.

SOD1 shows what ALS may often be: not one broken switch, but a collapsing economy inside the motor neuron. Different mutations start the collapse from different sides. SOD1 starts from a misfolded toxic protein and mitochondrial damage. TDP-43 may arise from RNA processing, stress granules, nuclear loss-of-function, and an increased autophagy burden. C9orf72 may start from repeat toxicity, RNA stress, and dipeptide repeat proteins. But downstream, many roads lead to the same place: the cell spends too much, earns too little, and dies first where the margin was smallest.

That place is the motor neuron.

8

C9orf72

The C9orf72 mutation is located in the C9orf72 gene on chromosome 9, specifically at chromosome 9p21.2.

The mutation itself is unusual because it is not a typical single DNA typo. Instead, it is a massive expansion of a short repeated sequence:

GGGGCC

This six-letter sequence normally repeats only a few times, perhaps a few dozen, in healthy people. In affected individuals, the repeat can expand to hundreds or even thousands of copies.

Importantly, the expansion occurs in a non-coding region between exons of the gene rather than within the protein-coding sequence. That initially led researchers to think it might be harmless. But the repeat turns out to be toxic in multiple ways:

- abnormal repeat RNA accumulates

- strange dipeptide repeat proteins are produced
- nuclear transport becomes disrupted
- stress granules are altered
- eventually, TDP-43 pathology appears

One reason C9orf disease is so devastating is that the mutation behaves less like a simple broken protein and more like a persistent intracellular contamination source. The cell continues transcribing the repeat-containing RNA, which then interferes with multiple systems, especially nucleocytoplasmic transport across the nuclear membrane.

* * *

C9orf72 gene repeat expansion is the most common ALS-linked mutation. Traditionally, it has been discussed in terms of toxic RNA foci, dipeptide repeat proteins, nucleocytoplasmic transport defects, and TDP-43 pathology. All of those are real. But from an energy perspective, they may be different faces of the same underlying problem: the mutation steadily worsens the metabolic balance of cells already operating near their energetic limits.

The C9orf72 mutation attacks that margin from multiple directions simultaneously.

One side of the problem is the production of abnormal RNA and dipeptide repeat proteins through repeat-associated non-ATG translation. Cells spend energy manufacturing proteins that serve no useful function and are often directly toxic. Protein quality control systems attempt to clear them through proteasomal degradation and autophagy. Both processes consume energy. The mutation, therefore, creates a chronic parasitic energy sink inside already stressed neurons.

Another side is nucleocytoplasmic transport failure. Transport across the nuclear membrane is not passive diffusion. It is an active, regulated, energy-dependent process. When transport becomes disrupted, proteins end up in the wrong compartments, RNA handling deteriorates, and the cell increasingly loses the ability to coordinate itself efficiently. Disorder itself becomes metabolically expensive.

The mutation is also strongly linked to stress granule pathology and eventually to the mislocalization of TDP-43. Maintaining this pathological semi-stressed state consumes further energy while simultaneously impairing the cell's ability to generate it efficiently.

This is where the energy hypothesis becomes compelling.

The mutation does not need to directly "kill" neurons in a conventional sense. It may simply push already marginal cells past the point where energy production can no longer sustain cellular housekeeping. Once the balance turns negative, maintenance begins to fail gradually:

- axonal transport slows
- mitochondria become dysfunctional
- protein aggregates accumulate
- ion homeostasis destabilizes
- calciu m buffering weakens

- oxidative stress increases
- repair systems fall behind

At first, the neuron compensates. Motor neurons are remarkably resilient cells. But compensation itself costs energy. Eventually, the system enters a downward spiral where every adaptation further worsens the deficit.

This may also explain why C9orf72 disease is so variable.

Different individuals begin with different metabolic reserves, mitochondrial efficiencies, stress tolerances, inflammatory environments, and lifestyles. The repeat expansion itself may remain constant while the energetic balance around it differs enormously. The disease then appears heterogeneous, even though the underlying failure mode is similar.

It also explains why neurons spread pathology selectively. Cells under chronic energetic stress release abnormal proteins, vesicles, and inflammatory signals. Neighboring neurons already near their own energetic limits become less able to maintain proteostasis. The pathology, therefore, propagates preferentially through the most metabolically vulnerable networks.

Seen this way, the mutation is not merely a genetic switch that "causes ALS." It is a persistent destabilizer of cellular energy economics.

And perhaps most importantly, this perspective explains why single-target therapies repeatedly disappoint in Amyotrophic Lateral Sclerosis. If the disease arises from a cumulative energy imbalance driven by multiple interacting pathways, blocking a single downstream mechanism may yield little visible benefit. The system simply continues collapsing through the remaining routes.

The mutation simultaneously disrupts RNA handling, protein homeostasis, intracellular transport, mitochondrial function, and stress responses. All roads converge on the same endpoint: cells no longer possessing enough usable energy to maintain themselves.

From that perspective, motor neuron degeneration starts to look less like a mysterious selective curse and more like an engineering problem of a system operating permanently beyond its sustainable power budget.

9

Apoptosis

Apoptosis is cellular suicide carried out with discipline.

Not collapse. Not an explosion. Not chaos.

A cell undergoing apoptosis does not simply fail. It follows a genetically encoded dismantling program designed to remove it while causing as little damage to surrounding tissue as possible. The membrane stays mostly intact. The contents are packaged into small fragments. Nearby immune cells quietly clear the remains away. In healthy tissue, apoptosis happens constantly and almost invisibly.

Without it, multicellular life would not work.

During embryonic development, apoptosis shapes the body. Human fingers begin as paddle-like structures. Cells between them are instructed to die, so separate fingers emerge. The nervous system initially produces far more neurons and synaptic connections than will ultimately survive. Those unable to establish stable functional integration are eliminated. Biology overproduces first, then refines through selective death.

The same logic continues throughout life.

Cells accumulate mutations. DNA breaks. Proteins misfold. Mitochondria fail. Viruses hijack cellular machinery. At some point, a damaged cell becomes more dangerous alive than dead. Apoptosis is the mechanism by which the organism protects itself from its own components.

Cancer is, in many ways, a failure of apoptosis.

A malignant cell is often not merely one that grows rapidly, but one that refuses to die when ordered to. Tumor suppressor systems such as p53 normally monitor genomic integrity and cellular stress. When damage becomes excessive, they can activate apoptotic pathways. But cancer cells evolve ways around this. They disable death signaling, overexpress survival proteins, or mutate the sensors themselves. The result is a cell that keeps consuming resources and replicating even though it no longer serves the organism.

Neurons are different.

Most cells can be replaced. Motor neurons generally cannot. Once development is complete, their loss becomes effectively permanent. That creates a profound biological dilemma. A neuron under stress cannot casually choose apoptosis, because its disappearance may mean irreversible loss of function. Yet remaining alive while severely damaged may also threaten surrounding tissue.

This balance becomes especially important in neurodegenerative diseases.

In ALS, Parkinson's disease, Alzheimer's disease, and related disorders, neurons often exist for years in a state between healthy function and death. They accumulate abnormal proteins, undergo oxidative stress, exhibit metabolic deficits, mitochondrial dysfunction, impaired axonal transport, and inflammatory signaling. Some eventually cross the threshold into apoptosis or related death pathways. Others may linger in partially functional states for surprisingly long periods.

Apoptosis itself is highly energy dependent.

Even dying cleanly requires ATP. The cell must actively dismantle itself in an organized sequence: activate caspases, fragment DNA, reorganize membranes, and expose "eat me" signals to phagocytic cells. When energy becomes critically depleted, cells may fail to complete apoptosis properly and instead undergo necrosis - a far messier form of death involving membrane rupture, inflammation, and collateral tissue damage.

There is a big difference.

A neuron dying slowly under metabolic stress may not simply switch from "alive" to "dead." The entire trajectory depends on whether enough energy remains to maintain order during failure. Biology is full of systems that remain stable only as long as energy flow continues. Once energy falls below critical thresholds, regulation itself collapses.

Apoptosis, therefore, represents something deeper than death alone. It is a controlled surrender in service of the larger system. The individual cell is expendable, so the organism may survive.

Multicellular life is built on that principle.

* * *

In Amyotrophic Lateral Sclerosis, apoptosis appears to be one of the final execution mechanisms by which motor neurons disappear. The disease process may begin years earlier through protein aggregation, energy imbalance, oxidative stress, impaired RNA handling, mitochondrial dysfunction, excitotoxicity, or axonal transport failure, but eventually many neurons seem to cross a threshold where survival signaling can no longer be maintained. At that point, apoptotic pathways become activated.

Motor neurons are unusually vulnerable to this.

In healthy neurons, survival pathways constantly suppress apoptosis. The cell is effectively being told every moment: continue operating. Continue repairing. Continue maintaining membrane potential. Continue transporting cargo. Continue holding the synapse together.

But ALS pushes the system in the opposite direction.

Misfolded proteins such as TDP-43, SOD1, or abnormal dipeptide repeat proteins from C9orf72 accumulate inside neurons. Mitochondria become dysfunctional. Oxidative damage rises. RNA processing becomes impaired. Stress granules persist abnormally. Axonal transport slows. Calcium regulation is destabilized. The neuron enters a chronic stress state from which recovery becomes increasingly difficult.

Eventually, the balance shifts from "repair and survive" toward "terminate and remove."

One important pathway involves mitochondria. Under severe stress, mitochondrial membranes become permeable, allowing cytochrome c to be released into the cytoplasm. That acts as a death signal, activating caspases - specialized proteases that dismantle the cell from within. The neuron begins digesting its own structural proteins, fragmenting its DNA, and shutting down in an orderly manner.

In ALS, this process is probably not abrupt.

Many neurons appear to spend years in an unstable intermediate condition. Denervation and reinnervation cycles occur repeatedly. Surviving motor neurons sprout collateral branches to rescue abandoned muscle fibers, further increasing their workload. This compensation temporarily masks ongoing neuronal loss, but it also increases metabolic burden on the remaining cells. The system becomes progressively more fragile.

From an energy perspective, apoptosis may represent the point at which the neuron can no longer sustain the cost of remaining alive.

That is important because many ALS-associated mechanisms converge on cellular energetics even when their genetic origins differ greatly. Different upstream pathways, but many ultimately worsen the neuron's energy balance.

And apoptosis itself is not free.

A clean, regulated death requires ATP. Caspase cascades, membrane restructuring, controlled fragmentation, and signaling to phagocytic cells all consume energy. If depletion becomes severe enough, neurons may instead drift into more chaotic degenerative states characterized by necrosis, inflammation, and secondary tissue injury.

That may partly explain why neurodegeneration often looks slow, uneven, and regionally progressive rather than synchronized. Different neurons cross critical energetic thresholds at different times depending on morphology, firing burden, compensation load, and local support from surrounding glial cells.

The tragedy of ALS is therefore not simply that motor neurons die. Biology already expects cells to die. The tragedy is that these particular cells cannot realistically be replaced once lost. A skin cell undergoing apoptosis is routine maintenance. A motor neuron undergoing apoptosis may permanently erase a function that the body can never reconstruct.

10

A Stalling Airplane

A stalled aircraft is rarely destroyed by a single failure.

Usually, the sequence begins much earlier and much more quietly.

The aircraft starts losing power. Perhaps slowly enough that nobody initially notices. After a while, the pilot notices that the altitude is decreasing. The instinctive response is obvious: pull the nose up and maintain level flight. To the pilot, that feels like preserving control.

But an aircraft cannot cheat physics.

Raising the nose increases drag. Increased drag reduces speed. Reduced speed weakens the lift. Weakening lift demands an even higher angle of attack to maintain altitude. The aircraft enters a self-reinforcing loop:

- altitude is falling

- speed is falling
- compensation accelerates both

Eventually, the wing exceeds its critical angle of attack, and aerodynamic coherence collapses. The aircraft stalls.

Not because the pilot stopped trying, but because the recovery attempt itself consumed the remaining margin.

Motor neurons in Amyotrophic Lateral Sclerosis increasingly resemble this kind of failure.

* * *

Motor neurons are the most energy-challenged cells in the human body. Under normal conditions, this already places them close to metabolic limits.

In healthy aging, reserve gradually decreases, but slowly enough that the system remains stable. In ALS, however, something shifts the balance further.

Different ALS variants appear to push the system from different directions. The exact mutation or initiating event may differ, but many pathways converge toward the same outcome: an energy deficit in cells that were already operating near minimum safe speed.

The neuron responds exactly as biology has evolved it to respond: it attempts to preserve function.

Stress granules form to reorganize RNA handling. Autophagy increases to clear damaged proteins. Chaperone systems activate. Repair pathways intensify. Cellular signaling changes to stabilize the system.

These are not signs of biological stupidity. They are survival mechanisms.

But survival mechanisms also consume energy.

The neuron is effectively pulling the nose up.

The more stressed the cell becomes, the greater the fraction of its remaining energy budget is diverted to defensive processes rather than normal operation. The very systems intended to preserve stability begin worsening the energy deficit.

That is what makes the process so dangerous.

The collapse is not linear.

It is recursive.

* * *

This may also explain why ALS progression often appears deceptively stable for long periods before accelerating rapidly.

An aircraft can remain controllable surprisingly close to stall. Small adjustments still work. The pilot may even temporarily regain altitude. But the remaining margin becomes increasingly fragile. Eventually, a point is reached where even tiny disturbances become unrecoverable.

Similarly, motor neurons may compensate for years.

Then suddenly:

- axonal transport fails
- nuclear-cytoplasmic balance collapses
- TDP-43 accumulates outside the nucleus
- local energy delivery becomes insufficient
- synaptic connections are lost

The system no longer possesses enough "airspeed" to sustain organized function.

* * *

One of the most disturbing aspects of ALS is that the disease often appears highly selective.

Why motor neurons?

The stall analogy offers a simple answer.

Because they are already flying closest to the edge. The engine is underpowered for the massive airframe to begin with.

Most cells possess a substantial metabolic margin. Motor neurons do not. They are large, structurally extreme, continuously active, and energetically expensive. Evolution optimized them for performance, not robustness.

That means relatively modest disturbances in energy balance may selectively destabilize them long before other tissues fail.

In that sense, ALS may not be a disease of uniquely vulnerable proteins.

It may be a disease of uniquely marginal energy economics.

* * *

This also changes how one interprets protein aggregates.

Aggregates may not always be the original cause of failure. In many cases, they may instead represent the visible wreckage left behind after the system has already lost aerodynamic stability.

The stall came first.

The debris field appears afterward.

* * *

The cruel irony is that the neuron may destroy itself while attempting to survive.

Like a pilot desperately holding the aircraft level while unknowingly bleeding away the last remaining speed, the cell continues activating compensatory pathways long after the energy balance has become unsustainable.

And by the time the stall becomes visible externally, the process may have begun years earlier.

* * *

ALS progression often resembles an aircraft stall because the problem is not simply a lack of power but a progressive imbalance in energy, where the demands placed on the system gradually exceed what the body can sustainably support.

That is why overexertion is so dangerous in ALS, even though both patients and healthcare systems are often psychologically drawn toward the exact opposite approach.

When an airplane approaches stall, the instinctive reaction is often to pull the nose up harder to maintain altitude and preserve the appearance of controlled flight, but doing so only worsens the loss of airspeed until lift eventually collapses.

Recovery requires the opposite response: the nose must be lowered, and altitude deliberately sacrificed to regain speed and restore stable flight before total loss of control.

The same principle applies remarkably well to ALS.

Patients often try to preserve normality for far too long, forcing themselves to keep walking even when it becomes exhausting, continuing manual transfers even when they should no longer be attempted, and maintaining ordinary daily routines at almost any cost because surrendering those routines feels psychologically worse than the exhaustion itself.

But biology does not care about dignity, appearances, routines, or the emotional symbolism attached to independence.

It cares about energy balance.

The body can sometimes partially recover from a functional downward spiral if energy expenditure is aggressively reduced early enough, not because dead neurons regenerate — they do not — but because the remaining system may stabilize once chronic overload, respiratory strain, sleep disruption, and constant physiological stress are removed from the equation.

That recovery often looks deeply counterintuitive from the outside, because the patient may give up walking earlier than expected, move permanently to bed, begin using invasive ventilation, avoid physically demanding hygiene routines, minimize communication, and structure everyday life almost entirely around conserving physical effort rather than maximizing visible activity.

To outsiders, this may resemble surrender or defeat, especially in cultures that equate constant activity with strength and prolonged rest with giving up, but biologically, it may instead represent cutting the drag to avoid stalling.

This may also explain why some ALS patients plateau for years after periods of apparently rapid decline, because disease progression is not always a smooth, predetermined curve, and part of the apparent "progression" may actually consist of secondary collapse caused by chronic energy depletion, malnutrition, secretion burden, recurrent infections, respiratory work, poor sleep, or relentless physical strain superimposed on the underlying disease.

Once those secondary stressors are brought under control, long-term stability may become possible for some patients, even if the original neurological damage itself is not reversed.

An aircraft recovering from a stall does not magically regain lost altitude.

But it may continue flying.

11

Spreading

One of the most disturbing aspects of ALS is that it spreads through the body.

Symptoms may begin in one hand, one leg, or the bulbar region and gradually spread to neighboring regions over time. That raises an important question: how does the disease propagate from one group of neurons to another?

One proposed explanation is prion-like spreading.

Not necessarily in the classical infectious sense, but in the sense that abnormal proteins may force normal proteins into the same misfolded state.

Proteins such as TDP-43, SOD1, and FUS can misfold and aggregate. Once aggregates form, they may act as templates that destabilize nearby proteins. A damaged cell may then release abnormal protein fragments, vesicles, or aggregates into the extracellular environment, where neighboring cells absorb them.

The pathology effectively recruits new cells into the same failure mode.

But spreading is probably not just about protein contact alone.

A stressed neuron also changes its environment:

- inflammatory signaling increases
- surrounding glial cells become activated
- oxidative stress rises
- glutamate regulation may worsen
- local metabolic support deteriorates
- mitochondrial damage products accumulate

This means neighboring neurons are no longer operating under normal conditions. Their energy margin shrinks as well.

That may be critical.

A healthy neuron with a large reserve capacity might tolerate some misfolded proteins. But a motor neuron already operating near metabolic limits may not. Once one region becomes unstable, it can create a progressively more hostile environment for connected cells.

The spread may therefore involve both:

- transfer of toxic or misfolded cellular components
- transfer of metabolic stress

Axonal connections may also provide pathways for propagation. Motor neurons are highly interconnected with local support cells, spinal circuits, and long axonal transport systems. Vesicles, damaged mitochondria, RNA-binding proteins, and stress signals can move along these pathways.

In that sense, ALS progression may resemble cascading infrastructure failure more than isolated cell death.

One overloaded node begins failing.

That failure increases stress on neighboring nodes.

Those nodes then begin failing as well.

The outward pattern may appear to be “spreading,” even if the underlying trigger differs among patients.

This may also explain why progression often accelerates after a certain point. Once enough neurons and support systems are impaired, the remaining healthy cells assume a greater compensatory workload while operating in a worsening biochemical environment.

The system loses reserve.

And from that point onward, each new failure makes the next one more likely.

* * *

ALS pathology does not remain confined to a single neuron. Misfolded proteins, inflammatory signaling, mitochondrial stress, and cellular debris appear to spread dysfunction outward, gradually pulling neighboring cells into the same collapse. TDP-43 pathology behaves less like an isolated defect and more like a propagating process.

That immediately raises an important question: if neurons cannot easily be replaced, could the spread at least be slowed?

One possible approach is to reduce chronic inflammation. Activated microglia and astrocytes are meant to help damaged tissue, but in ALS, they may become part of a self-reinforcing cycle. Inflamed support cells release cytokines, reactive oxygen species, glutamate, and other stress signals, thereby increasing the metabolic burden on already struggling neurons. A motor neuron operating near its energy limit may tolerate normal conditions, but fail once surrounded by inflammatory noise.

The problem is that inflammation is not purely bad. The immune system also clears debris, removes damaged proteins, and supports repair. Completely suppressing it could even worsen the cleanup failure. The real goal would be preventing chronic overactivation without disabling maintenance functions.

This is one reason many ALS interventions appear frustratingly weak. The disease is probably not driven by a single pathway. Protein aggregation, mitochondrial dysfunction, impaired autophagy, excitotoxicity, axonal transport failure, and inflammation all interact. Once enough loops reinforce each other, the system may become self-sustaining.

Still, slowing the spread is important even without a cure. ALS progression is often uneven. Some regions remain functional for years while others fail rapidly. That suggests local conditions influence vulnerability. If the toxic environment around neurons can be made less hostile, remaining cells may survive much longer.

From an energy perspective, anti-inflammatory approaches are plausible because inflammation is metabolically expensive. Immune activation increases oxidative stress, ion-pumping demand, protein turnover, and repair workload. A neuron already struggling to maintain axonal transport over a meter-long axon may simply run out of reserve margin.

The same logic may partly explain why avoiding infections is so important in ALS. Pneumonia, chronic mucus retention, hypoxia, sleep disruption, or repeated aspiration do not merely stress the lungs. They increase whole-body inflammatory signaling and metabolic demand at exactly the moment the nervous system can least afford it.

Unfortunately, current medicine still treats many ALS complications as isolated problems rather than parts of one connected energy and stress network.

12

Life Can Be Good

A large fraction of the suffering associated with Amyotrophic Lateral Sclerosis does not come directly from neuron death. It comes from care systems that never truly adapted to the possibility of long-term survival.

For decades, the assumption was simple: ALS progresses, the patient deteriorates, death follows relatively soon, and aggressive adaptation is therefore unnecessary. Entire care cultures formed around that expectation. The goal shifted from enabling life to managing decline.

That assumption became self-reinforcing.

Patients were told life with paralysis would inevitably be miserable. Communication tools were primitive. Ventilation was framed as something extreme and undesirable. Long-term comfort strategies were underdeveloped. Energy conservation was poorly understood. Homes were not adapted properly. Patients were exhausted by constant unnecessary activity because caregivers often expected reciprocal social performance during every interaction.

Then the resulting exhaustion, depression, and poor quality of life were presented as proof:

"See, we told you."

But that is not an objective outcome of paralysis. It is the outcome of a system optimized for decline rather than adaptation. The problem is that healthcare systems still often treat patients as though they should quietly fade away.

Small things accumulate:

- exhausting transfers for nonessential routines
- unnecessary clinic visits
- poor communication setups
- badly designed interfaces
- inadequate cough assist access
- fragmented caregiver training
- excessive focus on "normal living" instead of sustainable living
- psychological pressure to mourn constantly instead of adapting

Many practices are designed from the perspective of healthy caregivers, not from the energy economy of a severely disabled patient.

A ventilator patient is effectively performing survival work 24 hours a day. Breathing, secretion management, positioning, communication, sleep quality, and energy conservation all become engineering problems requiring continuous optimization. If care ignores that reality, suffering rises dramatically.

Poor quality of life then becomes partly manufactured by the care environment itself.

This is especially visible in how society talks about dependence. Loss of mobility is automatically equated with loss of dignity. Yet many people with severe paralysis report stable or even good subjective quality of life once the initial shock passes and proper adaptations are in place. Humans adapt remarkably well when given time to establish a new equilibrium.

The bleakest narratives often come from observers imagining themselves in that situation, not from people actually living it.

Medicine historically controlled that narrative because paralyzed patients had limited ability to communicate publicly. Eyegaze and internet communication broke that monopoly. Patients can now describe their own lives directly, in real time, to thousands of people. That makes it increasingly difficult to maintain simplistic assumptions that severe disability automatically means unbearable existence.

The uncomfortable implication is that many deaths previously framed as inevitable consequences of disease may actually have involved preventable suffering, inadequate support, or failure to adapt care for long-term survival.

* * *

The argument that life with a ventilator is pointless because "you will never get better" makes little sense when compared to how society already views countless other chronic conditions. A person with a pacemaker will not suddenly regrow a healthy cardiac conduction system either. A spinal cord injury patient in a wheelchair is usually not expected to walk again. A type 1 diabetic does not "recover" from needing insulin. Even eyeglass users will probably need them for the rest of their lives. Yet nobody concludes that their lives are therefore not worth continuing.

Invasive ventilation in ALS falls into the same category. The ventilator does not cure motor neuron loss. It replaces one failed subsystem of the body.

What often makes ventilator treatment controversial is not the machine itself, but society's assumptions about paralysis. Many people silently equate physical dependence with loss of personhood. They imagine that if someone cannot walk, dress themselves, or breathe independently, their life must automatically become unbearable. But that assumption is often made by healthy people imagining paralysis from the outside, not by those actually living it.

A ventilated ALS patient may still think, write, communicate, work, love, parent, joke, create, and contribute. Eyegaze technology alone already gives access to computers, communication, and the internet. The body may fail while the mind remains fully intact. In that situation, refusing life support simply because "you cannot get better" starts sounding less like medical reasoning and more like an arbitrary value judgment about whose lives are considered worth sustaining.

Medicine routinely accepts permanent dependency when the dependency is culturally familiar. Nobody asks a diabetic whether life is worth continuing because insulin will be needed forever. Nobody argues that a pacemaker patient should decline treatment because the heart will never heal naturally. Yet when the support device is a ventilator, the discussion suddenly shifts from engineering to philosophy.

That inconsistency reveals more about societal discomfort with visible disability than about the actual value of the patient's life.

* * *

People love to chime in on internet discussions about paralysis, ventilators, or severe disability to declare how they would "rather die than depend on others." It always gets applause. It sounds strong, decisive, and independent. But it is easy to say from a healthy body.

Have they really thought it through?

Does the principle also apply to old age?

Aging is, in many ways, a gradual accumulation of dependence. First come reading glasses. Then medications. Then maybe a walker, hearing aids, help with shopping, help with washing, eventually perhaps diapers or memory care. Very few people die at peak independence. Most spend years becoming progressively dependent on technology, medicine, infrastructure, or other humans.

Yet nobody praises an elderly person for refusing food because they need help eating. Dependence is accepted everywhere else. Only paralysis seems to trigger this theatrical performance of "I would never live like that."

What people usually mean is not dependence itself. They mean loss of status. Loss of the image they have of themselves. They imagine dependence as humiliation instead of adaptation.

But humans adapt surprisingly well. A person who becomes paralyzed does not spend every waking second comparing life to jogging or opening jars. The brain recalibrates. New routines form. Meaning shifts elsewhere. Communication, relationships, humor, curiosity, work, writing, politics, engineering, art - all remain possible long after walking disappears.

And importantly, the alternative is often imagined unrealistically. People speak as if death is some clean assertion of dignity made from a movie script. In reality, many conditions that create dependence do not immediately kill you. They simply leave you needing assistance while still very much wanting to think, talk, love, argue, learn, and exist.

Internet discussions reward dramatic declarations. "I would choose death" gets likes because it sounds brave. "I would adapt and continue living" sounds less cinematic. But the latter is what humans usually do. Including the people making those comments.

13

On Hope

When you understand what a motor neuron really is, you also understand why ALS is not a disease for the mentally weak.

A motor neuron is not merely a cell that can be swapped for another. During embryonic development, these neurons are formed early, then stretched and routed through a growing body with astonishing precision. Some extend axons over a meter long, navigating through tissues that themselves are still forming. Every connection is established once, through developmental processes impossible to recreate in an adult human body.

That is why a dead motor neuron is not simply “damaged.” It is gone.

The route cannot just be rebuilt. The body no longer possesses the developmental machinery that originally guided it into place. When the neuron dies, the function tied to it dies with it. A hand weakens. A foot drops. A voice fades. And eventually one understands a brutal reality:

You will never walk again.

Western culture prepares people very poorly for this kind of confrontation with permanence. We are raised on recovery narratives. We are taught that determination conquers all things. That every illness is a battle one eventually wins if one only fights hard enough.

ALS does not negotiate like that.

Some seek hope from prayer. Others from miracle cures, supplements, or statistics taken wildly out of context. But if one examines the actual numbers honestly, spontaneous reversals essentially do not happen. Clinging to the expectation of recovery often becomes its own form of suffering.

Paradoxically, survival mentally becomes easier only after giving up the idea of getting better.

Not giving up on life.

Giving up on reversal.

Those are not the same thing.

The goal must become smaller, more realistic, and therefore more achievable: preserve function as long as possible, adapt intelligently, remain useful, remain present, and continue contributing while the disease advances. That may sound bleak to healthy ears, but in practice, it can become strangely liberating. Once impossible expectations are discarded, energy can finally be spent on what still matters.

And meaningful contribution does not end with physical decline.

In fact, those whom medicine currently cannot save may have the greatest responsibility to advance understanding. ALS patients possess something researchers often lack: continuous direct observation of the disease from inside the system itself. Patterns become visible over the years. Triggers, adaptations, progression dynamics, energy limitations, recovery failures - these are not abstractions when one lives inside them every hour.

First and foremost, it is up to us whom medicine will not help in time to ensure we become the last generation left in that position.

ALS will probably never be "reversed" in the science-fiction sense people imagine. Dead motor neurons will not magically regrow across meter-long developmental pathways. But that does not mean the disease itself cannot be stopped.

Those are different problems.

Rebuilding a destroyed nervous system is extraordinarily difficult.

Stopping ongoing degeneration should be far easier.

And once one begins viewing ALS primarily as a failure of cellular energy balance in the most energy-stressed cells of the human body, many scattered observations suddenly begin aligning into a coherent picture. Different genetic variants attack different parts of the same fragile equation. Different pathways, same collapse.

That is why variant-indifferent treatments repeatedly fail.

And also why a real solution may ultimately emerge not from a single miraculous cure, but from finally understanding the underlying system-level physics of the disease.

14

A Societal Burden

Amyotrophic Lateral Sclerosis is usually discussed as a medical tragedy affecting individual patients and families. That is true, but it is no longer the whole picture.

Modern technology has quietly changed the meaning of severe paralysis.

Ventilators can replace respiratory muscles for decades. Feeding tubes can replace swallowing. Eyegaze systems can restore communication and computer access even after nearly all voluntary movement is lost. A fully paralyzed person may remain intellectually active long after the body itself has failed mechanically. This book, for example, was written in a couple of weeks, entirely unassisted, using only eyegaze technology.

For most of modern medical history, severe paralysis often led relatively quickly to silence, institutionalization, and death. Care systems evolved around that expectation. The goal was usually to manage decline rather than to support long-term survival. There was little practical reason to optimize communication systems, long-term comfort, energy conservation, or highly refined home care for patients assumed to have limited time remaining.

But technology moved faster than the surrounding culture. That creates tension that healthcare systems have not fully adapted to.

Long-term survival with advanced paralysis is expensive, labor-intensive, and structurally difficult. It requires caregivers, equipment, housing adaptation, respiratory support, communication systems, and continuous practical maintenance. At the same time, the number of patients wanting aggressive life support is gradually increasing because communication technology has made meaningful long-term survival more realistic than previous generations imagined.

The deeper issue is that society still tends to evaluate paralysis from the outside. Healthy people imagine loss of movement while unconsciously assuming that movement itself is the foundation of human existence. But humans adapt. Priorities change. Energy conservation becomes instinctive. Communication replaces physical activity as the primary interface with the world. Stability becomes more valuable than performance.

A ventilated patient with good communication tools, stable routines, effective secretion management, minimal unnecessary strain, proper caregiver training, and freedom to participate intellectually may experience life very differently from what healthy observers imagine. More and more patients will choose long-term survival. And unlike previous generations, they now have the ability to describe publicly what happens when support systems fail, adaptation is denied, or survival itself is discouraged or even denied.

Preventing paralysis in the first place is therefore the only sustainable way. We already have most of the pieces. It is time to get to work. Hopefully, this book will provide some inspiration.

* * *

Incurable diseases are not only a human tragedy. They are also a growing structural burden on society.

When a person develops a chronic, progressive disease, the costs extend beyond healthcare expenses. It spreads everywhere:

- lost productivity
- disability support
- long-term care
- reduced tax revenue
- exhausted families and caregivers
- shrinking workforce participation

And in aging societies, every net payer counts.

We still often talk about medical research as an expense. But curing or halting major chronic diseases is closer to infrastructure investment. Every person who remains healthy, independent, and able to work longer strengthens the entire system.

The problem is that many of these diseases are not simple. They are system-level failures involving metabolism, protein regulation, inflammation, signaling pathways, energy balance, the immune response, and feedback loops that interact over the course of decades.

That complexity has exceeded what humans can reliably model mentally.

But for the first time, we now have tools that can operate at system scale.

AI is not just faster statistics. Properly applied, it can analyze enormous multidimensional datasets, identify hidden interactions, recognize non-obvious patterns, and generate hypotheses that humans would never reach on their own.

That matters especially for diseases where reductionist approaches have stalled progress for years.

The potential value is enormous. Not only morally, but economically.

A cure for a major chronic disease does not merely save treatment costs. It returns people to life, work, creativity, and society itself.

In a world struggling with demographics, labor shortages, and rising healthcare costs, disease cures should increasingly be viewed not as consumption, but as investment.

* * *

A disease cannot simultaneously be described as too rare to justify serious research funding, yet so common and expensive that society cannot afford to keep willing patients alive.

Those two arguments directly contradict each other.

The confusion comes from mixing up prevalence and incidence.

ALS has low prevalence because it kills quickly. People do not live with it for decades the way they do with diabetes, spinal injuries, or many cancers. Short survival keeps the number of living patients artificially low at any given moment.

But incidence tells a different story.

Roughly 1 in 500 people will develop ALS during their lifetime. That is not some vanishingly rare lightning strike. In Finland alone, around 10 000 people currently alive today will eventually die of ALS if nothing changes.

Imagine if all of them suddenly knew it in advance.

There would be national panic. Emergency funding programs. Demands for accelerated drug development. Endless headlines asking why so little had been done.

But disease does not announce itself that way. It arrives one diagnosis at a time.

And so the reaction remains fragmented. Each newly diagnosed person feels isolated and asks, "why me?" even though hundreds of others are entering the same reality every year at that exact moment.

That isolation is partly an illusion created by statistics.

ALS does not look common because it does not leave many survivors behind to be counted.

* * *

For a long time, doctors effectively held a monopoly over the public narrative of paralysis. Patients with severe disability had little ability to communicate independently, little visibility, and almost no way to describe their own lives to society. What the medical system said became reality.

And decades ago, much of that narrative was true.

A quadriplegic patient without reliable communication was trapped behind other people's interpretations. Dependence was nearly total. Life became socially invisible. Physicians witnessed isolation, institutionalization, and progressive decline—and concluded that such a life was inherently unbearable.

But technology changed both sides of the equation.

Eyegaze communication gave fully paralyzed people direct access to computers. For the first time, patients could participate continuously in society rather than being spoken for by others.

That changed something fundamental.

The system could no longer describe paralysis only from the outside. Patients began documenting their own lives publicly. They started explaining in real time what existence with paralysis actually feels like from the inside.

The old narrative has not disappeared, but it is increasingly difficult to maintain.

Many physicians still operate psychologically inside a late 20th-century framework where invasive ventilation in ALS is viewed mainly as prolongation of dying rather than continuation of life. But the internet age makes information impossible to contain. Thousands of ventilator users now openly demonstrate that meaningful life after paralysis is entirely possible.

That creates tension that the healthcare system has not fully adapted to.

Every involuntary death now raises scrutiny. Every refusal of ventilation, communication access, cough assist support, or long-term care is discussed publicly by patients themselves. Explanations that once remained inside hospital walls are now compared internationally in real time.

At the same time, the number of ALS patients wanting long-term survival is growing. Society is slowly discovering that once communication and respiratory support exist, many patients do not actually want to die.

That creates an uncomfortable reality: providing long-term invasive support to large numbers of severely paralyzed people is expensive, labor-intensive, and structurally difficult. The temptation is to frame refusals as "medical futility" or "poor quality of life" even when the patient disagrees.

But that position becomes harder to sustain each year as patients continue speaking publicly for themselves.

In the end, there is only one durable solution.

We simply need to find a cure.

* * *

Paralysis does not make a person useless. It only changes the interface between the mind and the world.

Society often makes the mistake of measuring human value solely by physical productivity. That view belongs to an industrial era in which contribution was mainly associated with manual labor and mobility. But we now live in an information society. A person who can think clearly and communicate effectively can still contribute enormously, even from a bed and through a screen.

In many ways, severe paralysis exposes how primitive our assumptions about disability still are. People see an immobile body and unconsciously assume the person is absent-minded. Yet history is full of individuals whose physical limitations had little connection to the value of their intellectual work. The bottleneck is often not the disease itself, but whether society provides proper assistive technology and allows the person to keep participating.

Eyegaze communication is not merely a convenience device. It is a pathway of replacement between the brain and the outside world. Once that pathway exists, meaningful participation becomes possible again.

The real tragedy is not paralysis. The real tragedy is when society quietly gives up on people who are still fully capable of contributing.

* * *

The system has not fully understood what eyegaze technology means, as it still operates on assumptions from an earlier era of paralysis care. The old model depended heavily on silence, dependency, and gradual withdrawal from society. A person who could no longer speak or move eventually lost the practical ability to participate, question decisions, or resist institutional inertia. Communication itself became exhausting.

Eyegaze changes that.

A fully paralyzed person can now communicate independently and continuously. Not through an assistant interpreting fragments, but directly. That fundamentally changes the relationship between patients with paralysis and the healthcare system.

We no longer quietly agree to die.

Patients can compare treatment practices internationally, discuss experiences with others online, challenge outdated assumptions, and publicly document failures. We can coordinate our own care, follow research in real time, and demand explanations rather than passively accept whatever happens around us. The old expectation was that severe paralysis would naturally produce silence and compliance. Technology broke that expectation.

That shift is uncomfortable for institutions built around paternalistic care models. A ventilated quadriplegic lying motionless in bed still looks passive from the outside. But behind the eyegaze screen may be someone reading clinical papers, writing technical critiques, organizing advocacy, or exposing systemic failures in public.

The implications are enormous because the limiting factor is no longer physical movement. It is access.

Once communication bandwidth is restored, the patient ceases to be merely a target of care and becomes an active participant again. The healthcare system is still adapting to the fact that paralysis patients are no longer isolated individuals disappearing quietly behind closed doors.

We are online now.

15

Dealing With the Disease

Many people with ALS become obsessed with identifying the trigger. Was it pesticides, head trauma, stress, heavy exercise, military service, viral infection, welding fumes, bad luck, or something else entirely? The hope is understandable. If one specific event caused it, perhaps the disease could be mentally contained within that event. A clear enemy feels easier to accept than randomness.

But in practice, searching for the trigger is mostly pointless.

ALS is not like stepping on a landmine. It is more like walking on ice that has already become dangerously thin. The final crack may occur under a single specific footstep, but the important point is that the ice was already close to failure. Another step, another day, another stressor would likely have produced the same outcome sooner or later.

The nervous system was already operating near its limits. The body just didn't warn.

That is why ALS triggers are so inconsistent and frustrating to study. One patient exercised heavily. Another never did. One smoked. Another lived perfectly "healthy." One had head injuries. Another had none. The actual trigger matters far less than the pre-existing fragility.

A healthy motor neuron can tolerate enormous stress for decades. An already compromised one cannot.

This also explains why arguing over single risk factors often becomes misleading. Even if a factor statistically increases ALS risk, it does not mean it "caused" the disease in the simple sense people want. It merely nudged an already unstable system slightly closer to collapse.

And once symptoms begin, obsessing over the trigger serves little purpose anyway. The disease does not care whether the first domino fell because of exercise, infection, toxins, or chance. The practical problem remains the same: surviving with a nervous system that has lost much of its reserve capacity.

For many patients, accepting that reality is psychologically healthier than endlessly replaying the past, looking for the fatal mistake. There probably never was a single mistake.

* * *

In Finland alone, roughly 200 new people are diagnosed with ALS every year. That is not a cosmic anomaly. That is a steady stream of human beings entering the same nightmare, year after year.

So the question is not really "why me?" The statistics already guarantee that someone will be next. The only uncertainty is who.

Rare diseases create an illusion of uniqueness because patients are scattered. One person in one town. Another somewhere else. Most never meet each other. But when viewed at the scale of a country or the world, ALS stops looking like an isolated tragedy and starts looking like a persistent biological failure mode that medicine still does not understand.

And that changes the perspective. Instead of endlessly searching for a single personal mistake that "caused" the disease, it is more rational to ask what makes motor neurons so vulnerable in the first place, why different genetic variants converge on the same outcome, and why modern research still struggles to stop the process once it begins.

The tragedy is not that ALS strikes one unlucky individual. The tragedy is that it keeps striking thousands of people in such a similar way, and we still largely react as if each case were some mysterious exception.

* * *

Thinking is poison for the ALS brain. Not because thoughts themselves are dangerous, but because the diseased nervous system has no energy reserves left for endless internal processing. The healthy brain can afford anxiety spirals, philosophical debates about meaning, regret over the past, or fear of the future. The ALS brain often cannot.

Patients are constantly encouraged to “process” their situation psychologically. To talk. To analyze. To revisit grief again and again. But every hour spent mentally circling around the disease is an hour spent feeding stress pathways that already run too hot. Stress is not abstract. It is chemistry. Cortisol, sympathetic activation, fragmented sleep, elevated metabolic demand, muscle tension, and increased respiratory effort. In a disease that may fundamentally be about energy failure, this is gasoline on the fire.

Many patients intuitively discover something medicine rarely says aloud: denial is not always pathological. Sometimes it is adaptive energy management. Keeping the mind occupied with ordinary things, technical hobbies, television, online discussions, routines, humor, politics, sports, engineering problems, anything except constant self-analysis, may be profoundly protective.

The worst moments often come not from paralysis itself, but from sitting still and thinking about paralysis.

An ALS patient should therefore avoid becoming a full-time observer of their own decline. That mindset consumes enormous mental bandwidth while producing nothing useful in return. The disease progresses whether one monitors it obsessively or not. There is no prize for perfect psychological insight into one’s own degeneration.

Keep yourself busy instead.

Not physically busy. Energy must still be conserved carefully.

But mentally occupied. Give the brain tasks other than fear. Read. Write. Build things digitally. Argue online. Watch documentaries. Follow projects. Maintain routines. Continue participating in society in whatever form remains possible.

A mind focused outward survives better than a mind collapsing inward.

* * *

There is a particular danger in thinking too much about your own condition when facing a progressive disease. Not because reflection itself is wrong, but because the brain was never designed to sit still and endlessly analyze irreversible loss.

The human mind evolved to solve problems through action. You see danger, you run. You feel hungry, you search for food. Even grief traditionally came with movement, ritual, work, and survival. But in diseases like Amyotrophic Lateral Sclerosis, many of the losses cannot be repaired, avoided, or negotiated. The normal reward loop of “think - act - improve” breaks down.

And once that happens, excessive introspection becomes corrosive.

You begin replaying the same questions endlessly:
Why me?
What if I had noticed earlier?
What exactly is failing now?
How much time remains?
Will the next symptom be worse?

Could this have been prevented?

The problem is not merely emotional suffering. The problem is that the brain keeps consuming energy chasing solutions that do not exist. It becomes a machine spinning against locked brakes.

Over time, this can narrow a person's world until the disease becomes their entire identity. Every twitch is analyzed. Every weakness becomes a prediction. Every bad day becomes a prophecy. The mind starts amplifying noise into certainty.

Ironically, excessive focus on one's own decline may indirectly worsen physical well-being. Stress alters sleep. Poor sleep worsens cognition and emotional control. Anxiety reduces appetite. Isolation removes stimulation. Rumination replaces meaningful activity. Life slowly reorganizes itself around monitoring damage.

At some point, many people discover something unexpected: psychological survival often requires downplaying the disease in daily thought.

Not denying it. Not pretending it is curable. But refusing to grant it a monopoly over consciousness.

There is a major difference between:
"I have ALS"

and
"ALS is all that exists in my life."

The latter destroys people long before biology does.

Paradoxically, many long-term survivors seem to converge toward a similar mindset. They stop negotiating with reality. They stop waiting for emotional permission to live again. They stop treating every day as a medical emergency. Instead, they redirect attention outward.

Disease remains. But it no longer occupies the entire cognitive landscape.

This is not surrender. It is resource allocation.

The mind has finite bandwidth. Spending all of it staring into darkness guarantees only that darkness fills the field of view.

* * *

Well-meaning psychological counseling can sometimes become harmful in severe progressive disease if it assumes that constant emotional processing is always beneficial.

Many therapeutic models are built around the idea that healing comes from confronting emotions directly, verbalizing fears, revisiting trauma, and dismantling denial. That may work well for temporary crises or conditions where recovery is realistically possible. But in illnesses like Amyotrophic Lateral Sclerosis, the situation is fundamentally different. The threat is not imagined. The losses are not symbolic. The progression is not a cognitive distortion.

Sometimes, the most psychologically stabilizing strategy is not deeper immersion into the disease but partial disengagement from it.

Denial is often portrayed as pathological, but mild denial can be an adaptive protective mechanism. In practice, it may simply mean:

- not thinking about the disease every waking hour
- postponing emotionally overwhelming conclusions
- focusing on ordinary routines instead of prognosis
- refusing to mentally rehearse future disability constantly
- allowing the brain periods where life still feels normal

That is not necessarily irrational. It may be essential cognitive self-preservation.

A person who insists on discussing death, progression, fear, grief, and acceptance every week may eventually become psychologically trapped inside the disease narrative itself. The illness grows larger because attention continuously feeds it. The patient may leave counseling sessions feeling worse, not because the therapy failed technically, but because it repeatedly drags consciousness back into the very thoughts the mind was trying to keep compartmentalized in order to function.

Humans are not designed to stare continuously at an irreversible catastrophe.

In some cases, excessive insistence on "acceptance" can even become subtly coercive. Society often treats emotional con-

frontation as morally superior:
"You must process this."
"You must face reality."
"You must accept what is happening."

But functioning matters more than philosophical purity.

If a person manages to preserve motivation, humor, work, relationships, or future-oriented thinking through selective denial, distraction, compartmentalization, or controlled avoidance, destroying those mechanisms in the name of psychological correctness may be deeply counterproductive.

The goal should not be forcing patients into permanent confrontation with suffering. The goal should be to help them continue living despite it.

Sometimes survival depends less on fully accepting reality than on refusing to let reality occupy the entire mind.

* * *

By 2014, my wheelchair had already become more of a burden than a freedom. Every transfer cost energy. Every repositioning consumed strength that never fully returned. Sitting upright itself became work - muscles fighting gravity hour after hour while the body was already running an impossible energy deficit.

So the wheelchair was abandoned early.

Since then, life has been lived almost entirely in bed, day and night.

To outsiders, that sounds like surrender. In reality, it was optimization.

ALS is often described as paralysis, but long before total paralysis arrives, it becomes an energy economy. Every action has a cost. The body no longer has reserve capacity. Tasks healthy people classify as “doing nothing” may consume a meaningful fraction of the remaining metabolic margin.

The mistake many make is trying to preserve the appearances of normal life for too long.

Wheelchairs symbolize activity, independence, and participation. Beds symbolize defeat. But symbols are irrelevant to survival. The disease does not care what something looks like socially. It only cares about energy balance and physiological strain.

Giving up the wheelchair early conserved both.

Less physical stress. Less orthostatic strain. Less time fighting posture. Fewer exhausting transfers. Fewer situations where breathing mechanics worsened from fatigue. More energy remained for thinking, communicating, parenting, and simply staying alive.

Western culture teaches people to resist decline at all costs, as if adaptation itself were failure. But in ALS, stubbornness is often destructive. Survival depends less on “fighting” the disease theatrically and more on learning where energy is wasted and cutting those losses without sentimentality.

The bed was not the end of life.

It was what allowed life to continue.

16

The Eyegaze UI

One of the stranger absurdities of paralysis care is how often eyegaze communication is demonstrated on some tiny tablet-sized screen, as if the goal were merely to prove that communication is technically possible. Yes, it works. In the same sense that watching TV through a keyhole "works."

Effective long-term eyegaze work requires a large display. 27 inches is not luxury. It is ergonomics.

Human gaze is not a precise pointing device. It constantly jitters at the microscale, even in healthy people, and calibration is never perfect. On a small screen, buttons and letters become physically too close together. The user must keep their eyes tense and continuously concentrate just to avoid accidental selections. That turns communication into exhausting target shooting.

A larger screen changes everything. Targets become physically larger and farther apart. The eyes can move naturally, rather than straining for pixel-level precision. You can relax your face and neck. Accuracy improves because the system no longer demands an impossible level of exactness from human biology.

Most importantly, a large screen enables real computer work rather than survival-level communication. Writing long texts, editing documents, programming, controlling a smart home, browsing the web, participating in society - all of that becomes practical only when the interface stops fighting the user.

People often underestimate how mentally exhausting inaccurate eyegaze use is. If every word requires intense concentration, communication itself becomes a source of fatigue. A properly sized monitor reduces that cognitive load enormously.

Eyegaze is not merely a replacement keyboard. For many completely paralyzed people, it is the only remaining interface to the outside world. Designing that interface around portability instead of usability is like giving someone a wheelchair with square wheels because it folds nicely.

* * *

Healthy UI developers tend to miss two things about eyegaze typing.

First, typing produces a huge number of errors. Some are accidental. Some are deliberate. Direct vertical eye movement is difficult and tiring, so users often intentionally overshoot horizontally and then correct back rather than trying to land precisely on a small target. Because of that, backspace becomes one of the most important keys on the entire keyboard.

The best placement is a corner. Corners are easy targets because the gaze can simply be thrown against the screen edge without precise stopping. A corner effectively acts as an infinite target in two directions. That makes repeated correction much less tiring than trying to hit a small floating button somewhere inside the keyboard area.

Second, word prediction often does more harm than good. The problem is that the suggestion area flickers constantly as letters are entered. New words appear, disappear, reshuffle, and compete for attention. Human vision is extremely sensitive to motion and change in the peripheral field. The eyes are involuntarily drawn toward the constantly updating predictions even when the user is trying to ignore them.

That breaks concentration and interrupts the typing rhythm. Instead of flowing through a sentence, the user is repeatedly distracted by the interface itself. Finger typists can often ignore this because their hands operate partly from muscle memory while their vision focuses elsewhere. Eyegaze users do not have that separation. The eyes are both the pointing device and the visual system simultaneously. Any unnecessary visual activity directly interferes with control.

The important thing is not maximum demo typing speed measured over one minute, but whether the interface remains comfortable and mentally quiet after hours of continuous communication.

* * *

With eyegaze, formatted text is a nightmare to edit.

Healthy people do not realize how much editing relies on fast, precise cursor movement. A mouse user instantly clicks the exact spot, selects text in one motion, drags paragraphs around, and fixes mistakes almost subconsciously. The physical cost is negligible.

Eyegaze turns every one of those actions into work.

Moving the cursor into formatted text is slow because the targets become unpredictable. Different font sizes shift line spacing. Bold sections change word shapes. Lists, headings, links, tables, and embedded elements break the visual flow. The cursor easily lands in the wrong place. Correcting that mistake requires another sequence of deliberate gaze movements.

And every editing operation carries risk.

A small mistake may not just insert a wrong letter. It may destroy formatting, move an image, collapse a paragraph structure, create accidental selections, or overwrite entire sections of text. Or even reload the document. Recovering from that with eyegaze can take far longer than the original writing itself.

This changes behavior. You become reluctant to touch already finished text because the probability of making it worse is too high. Even minor corrections start feeling dangerous.

Selecting text is especially bad. With eyegaze, selection often means dwelling precisely at two tiny points one after another, while the system interprets intent correctly. In richly formatted text, the boundaries of words, lines, and paragraphs become harder to predict. A small mistake may cause the selection to collapse entirely or jump to an unexpected location.

Then comes scrolling.

A healthy user scrolls continuously while automatically keeping track of context. An eyegaze user may lose the insertion point completely after even a modest layout shift. Recovering it costs both time and concentration.

This is why many experienced eyegaze users prefer plain-text editors over “modern” rich-text environments. Plain text keeps everything stable. The cursor behaves predictably. Line spacing stays constant. Copying, correcting, and navigating require fewer eye movements and fewer recovery operations.

Formatting also creates anxiety during writing itself. If every correction is expensive and risky, you start avoiding corrections altogether. The writing flow becomes cautious and fragmented. Thoughts are simplified not because the user lacks ideas, but because editing overhead becomes too high.

Healthy designers often optimize for visual richness. Eyegaze users optimize for editability.

17

The Cough Assist

In long-term ALS survival, the second most important device after invasive ventilation is probably the cough assist machine. In practice, the two are tightly linked. The real advantage of invasive ventilation over noninvasive ventilation is not merely more stable breathing support. It is that airway clearance becomes far more effective.

A ventilator can move air in and out. But if secretions accumulate and cannot be cleared, the patient still dies - usually from pneumonia, mucus plugging, or gradual collapse of lung function. Respiratory failure in ALS is often presented as a problem of weak breathing muscles alone. In reality, a weak cough is just as dangerous.

The normal cough reflex is an extraordinarily powerful mechanism. It generates very high expiratory flow rates that clear mucus, saliva, food particles, bacteria, and inflammatory debris from the airways. ALS progressively destroys this capability. Once cough strength falls below a critical threshold, secretions begin to remain in the lungs. Infection risk rises sharply. Oxygenation worsens. Each infection leaves the lungs weaker than before.

This is where cough assist becomes essential. The machine rapidly alternates positive and negative pressure, simulating a natural cough with far greater effectiveness than ordinary suctioning. Used properly and early enough, it can clear deep secretions that would otherwise remain trapped. In many cases, it is the difference between staying at home and ending up intubated in intensive care.

Yet the healthcare system often treats cough assist almost as an afterthought. Ventilation gets discussed. Oxygen saturation is monitored. But airway clearance receives surprisingly little emphasis. Some patients are never introduced to cough assist. Others are denied access because they do not fit rigid criteria. Sometimes the machine is available, but training is inadequate, and usage remains too timid to be effective.

The consequence is predictable. Patients die from pneumonia that could likely have been prevented.

Once invasive ventilation is established, cough assist often becomes more effective because the tracheostomy provides a direct airway. The pressures transmit better. Secretion clearance becomes more reliable. For many long-term survivors, aggressive airway clearance is as important as the ventilator itself.

The system tends to frame ALS as an inevitably fatal neurodegenerative disease. But many deaths attributed to ALS are, in practice, deaths from poor secretion management. There is a difference.

Motor neurons may not recover. But mucus can still be removed.

* * *

ALS often becomes a respiratory disease long before it becomes a purely oxygenation problem. The danger is not only weak breathing, but also weak coughing. Mucus stays in the lungs, small airways collapse, infections accumulate, and eventually the patient enters a cycle of repeated pneumonias, hospitalizations, and progressive loss of lung function.

Many people focus on tracheal suctioning as the answer. But suctioning mainly removes secretions that are already in the central airway. It does little to address the deeper problem: mucus trapped deep in poorly ventilated lung regions, where the patient no longer has the muscle strength to generate an effective cough.

A better strategy may be preserving the ability to clear the lungs without invasive airway trauma. That is where cough assist devices become critical.

A mechanical insufflation-exsufflation device effectively replaces the missing cough reflex. It pushes air into the lungs and then rapidly reverses flow outward, creating the high expiratory flow needed to mobilize secretions from deep airways toward the throat. Instead of repeatedly inserting suction catheters into an increasingly fragile airway, the lungs are cleared more physiologically by airflow.

Trendelenburg positioning adds another overlooked advantage.

By placing the body with the head lower than the chest, gravity begins to help move secretions from lower lung regions toward the central airways, where cough assist can remove them more effectively. In patients with weakened lungs, gravity may become part of the respiratory support system.

Combining the two has several advantages:

- less airway trauma than repeated tracheal suctioning
- better mobilization of secretions from deep lung regions
- reduced risk of mucus plugging and atelectasis
- fewer infections caused by retained secretions
- better preservation of lung compliance over time

Repeated suctioning can become a vicious cycle. The airway becomes irritated, secretions increase, coughing weakens further, and deeper mucus remains untouched. The intervention treats the symptom visible at the tube - not necessarily the mechanics of secretion transport throughout the lungs.

It also carries an infection risk if high hygiene standards are not followed.

Long-term survival in ALS may depend less on “removing mucus from the trachea” and more on preserving an entire secretion-clearing system despite failing muscles.

The body originally evolved to clear the lungs using airflow, pressure changes, posture, and cough mechanics together. Cough assist and positioning attempt to restore that system artificially after the muscles can no longer do it alone.

* * *

One of the strangest realities in ALS care is that the most important life-prolonging device - the cough-assist machine - is still met with hesitation in many places.

The reasoning is not entirely irrational. Mechanical insufflation-exsufflation is not completely risk-free. Aggressive pressure swings can occasionally irritate the airways, cause small lung injuries, or, in rare cases, contribute to pneumothorax. More commonly, treatment may loosen large mucus plugs that the patient cannot adequately clear without proper suction and monitoring.

For physicians trained primarily to avoid immediate procedural complications, this creates discomfort. A patient may appear relatively stable while quietly accumulating secretions over weeks or months. The danger remains mostly invisible. Then, cough assist is initiated, secretions mobilize dramatically, and suddenly the situation becomes acute and highly visible.

The irony is that this often means the device is blamed for revealing the problem rather than for causing it.

Without cough assist, the same patient may simply progress toward pneumonia, chronic hypoxia, atelectasis, respiratory exhaustion, and eventual death in a slower and less conspicuous manner. That trajectory appears “natural.” The death certificate says ALS or pneumonia. Nobody feels directly responsible.

This creates a subtle but powerful bias throughout medicine. Slow deterioration caused by insufficient support is psychologically easier for the system to accept than a visible complication associated with active intervention.

One neurologist summarized this mentality with brutal honesty: “It is better that the patient dies of disease rather than treatment.”

From an institutional risk-management perspective, that statement is understandable. From the patient’s perspective, it is horrifying.

The problem is that ALS patients rarely die because motor neurons suddenly vanish overnight. They often die from secondary consequences:

- secretion retention
- ineffective cough
- recurrent infections
- exhaustion
- hypoventilation
- progressive collapse of airway

Cough assist directly targets one of the disease’s central mechanical failures: the inability to generate sufficient expiratory flow to clear mucus.

Healthy people unconsciously constantly clear small secretions. ALS patients gradually lose that ability. Mucus then accumulates silently until infection, obstruction, or hypoxia develops.

At that stage, avoiding the cough assist because of theoretical risks starts to resemble refusal to use seatbelts, since bruises occasionally occur during accidents.

Of course, proper use is very important. Pressure settings must be individualized. Patients require supervision during adaptation. Suction capability should exist when necessary. Extremely fragile lungs deserve caution. But these are arguments for competent use, not for avoidance.

The deeper issue is that medicine often evaluates interventions asymmetrically.

The risks of active treatment are counted precisely and documented immediately.

The risks of undertreatment are diffuse, delayed, and easier to attribute to “disease progression.”

In ALS, this distinction can become deadly.

A patient slowly drowning in retained secretions may look medically inevitable. A patient experiencing temporary distress during aggressive secretion clearance looks like a treatment complication. Yet the first scenario may be far more dangerous in the long run.

From an energy perspective, the consequences are obvious. Retained mucus increases airway resistance, worsens oxygen transfer, increases infection risk, and forces exhausted respiratory muscles to work continuously harder. The nervous system spends enormous energy merely trying to maintain ventilation through partially obstructed lungs.

Cough assist does not cure ALS. But by preserving airway clearance, it may substantially reduce one of the major downstream mechanisms by which ALS patients actually die.

18

Survival Tips

The hardest thing to accept about ALS is not necessarily the disease itself. It is realizing that the system is not truly organized around keeping you alive for as long as possible.

At first, you assume otherwise. Modern medicine appears immensely capable. Intensive care units can sustain failing organs. Ventilators can breathe for people indefinitely. Nutrition can be delivered artificially. Infections can be treated. Monitoring technology is extraordinary. The technical ability to prolong survival absolutely exists.

But capability and intent are not the same thing.

What the healthcare system optimizes for is not necessarily what the individual patient values most.

The system optimizes for standardized pathways, predictable resource use, statistical outcomes, legal defensibility, and manageable workloads. It is built around populations, not outliers. Around averages, not stubborn individuals determined to survive twenty years with a disease that statistically should have killed them long ago.

That difference slowly becomes visible after diagnosis.

Nobody explicitly tells you to die. The system is far more subtle than that. Instead, the entire structure quietly nudges you toward acceptance. Toward palliative framing. Toward comfort. Toward "quality of life" conversations that often begin astonishingly early, sometimes before you have even fully understood what is happening to your body.

The assumption underneath many interactions is not "How do we maximize long-term survival?" but rather "How do we manage the progression humanely?"

Those are not the same question.

Once you notice the distinction, you start seeing it everywhere.

You realize there is enormous emphasis on helping patients emotionally accept decline, but comparatively little emphasis on aggressively preventing secondary deterioration. You receive explanations about terminal illness, but not necessarily detailed education about secretion management, atelectasis prevention, respiratory muscle preservation, sleep optimization, or the mechanics of maintaining long-term pulmonary stability.

The system is reactive.

Long-term survival requires being proactive.

That gap changes everything.

Motor neurons die only once. Respiratory capacity lost to chronic under-ventilation may never fully recover. Repeated infections leave scars. Weight lost during hypermetabolic stress can become impossible to regain. Small declines accumulate into irreversible thresholds.

But institutional medicine often waits until thresholds are met before acting.

Ventilation support may be delayed until significant nocturnal hypoxia has already developed. Cough assist, if introduced at all, comes after recurrent infections rather than before them. Nutritional intervention may begin only after visible weight loss. Physical support equipment appears after function is lost, not while it might still preserve energy and reduce overuse.

This is how systems behave when designed around standardized criteria instead of aggressive optimization.

From an administrative perspective, thresholds make sense. They create measurable decision points. They ration resources. They reduce unnecessary interventions across large populations.

But ALS does not progress according to administrative convenience.

By the time many official criteria are fulfilled, irreversible damage may already have occurred.

That is when many patients and families begin discovering an uncomfortable truth: survival in ALS is largely DIY.

Not because doctors are evil. Most genuinely care. Many work extremely hard under impossible constraints. But they operate inside a structure whose goals only partially overlap with yours.

If your primary goal is maximal survival, eventually you are forced to become your own systems engineer.

You start collecting data. Watching trends. Measuring sleep quality, oxygenation, secretion burden, cough effectiveness, fatigue patterns, positioning effects, hydration, calorie intake, infection frequency, and response to interventions. You stop viewing your body emotionally and start viewing it as a deteriorating but manageable physical system whose failure modes must be anticipated early.

You learn things nobody formally teaches.

You learn that ineffective coughing can kill more reliably than the primary neurodegeneration itself. You learn that a weakened diaphragm deteriorates faster under chronic overload. You learn that sleep quality becomes a part of respiratory therapy. You learn that posture changes gas exchange. You learn that surviving severe disability often depends less on dramatic breakthroughs than on hundreds of tiny practical optimizations accumulated over years.

Most of this knowledge spreads informally.

Patients teach patients.

Caregivers teach caregivers.

Internet forums quietly preserve survival strategies that official medicine barely discusses. Families invent mechanical solutions. Positioning techniques. Suction adaptations. Ventilator settings. Communication workarounds. Nutritional approaches. Airway clearance routines.

An enormous amount of real-world ALS survival knowledge exists outside formal guidelines.

And the reason is simple: guidelines are not primarily written for exceptional long-term survival. They are written for broad applicability across entire healthcare systems.

Those are fundamentally different design goals.

Eventually, another realization follows, one even more unsettling.

Once you become severely disabled, society itself starts treating your continued existence as negotiable.

Again, not openly. Rarely maliciously. Just structurally.

Research funding remains limited due to the small patient population. Expensive equipment is questioned. Bureaucracies move slowly because your future economic productivity is assumed to be low. Public discussions celebrate acceptance more comfortably than endurance. People instinctively frame severe disability as a state from which death is almost a relief.

And if you survive far longer than expected, reactions become strangely conflicted.

You can sense that you were not really expected to still be here.

Modern societies are psychologically comfortable with acute rescue. They are much less comfortable with long-term severe dependency combined with fully preserved intelligence and awareness. A patient who remains mentally sharp while physically devastated exposes uncomfortable weaknesses in how society values human beings.

So long-term survivors often become unusually independent thinkers.

They stop assuming standard care equals optimal care. They begin treating guidelines as minimum standards rather than final answers. They learn when to cooperate with the system, when to pressure it, and when to work around it entirely.

At some point, you stop waiting for anyone else to take command of the situation.

You realize nobody is coming with a master plan.

There is no hidden team secretly optimizing every variable for your survival. No institution systematically integrating all the fragmented knowledge. No universal protocol that will carry you safely through the next decade.

There is just you, your caregivers, scattered expertise, partial information, and an unforgiving disease.

So you build your own system.

You experiment carefully. You adapt continuously. You keep what works. Discard what does not. You think less like a passive patient and more like the operator of a failing but repairable machine that requires constant supervision.

And paradoxically, that shift in mindset may itself become one of the most powerful tools of all.

* * *

A ventilator patient is never "off duty."

Breathing itself has become a managed process. Positioning matters. Secretions matter. Interfaces matter. Sleep quality matters. Every unnecessary exertion has a physiological cost that healthy people rarely understand. Energy is no longer a comfort issue. It is a survival margin.

Yet many nurses and caregivers unconsciously expect reciprocity during their shift. Conversation. Participation. Social engagement. Reassurance that their presence is appreciated. Constant responsiveness. The patient is expected to help carry the interaction.

But the patient is already working 24/7.

Typing requires effort. Eye contact requires effort. Holding attention requires effort. Remaining awake for someone else's comfort requires effort. The body is continuously balancing ventilation, fatigue, airway clearance, discomfort, and energy depletion.

This changes the priorities completely.

The patient's job is not to entertain the staff. It is not to provide a pleasant social experience for every shift worker who enters the room. The patient's responsibility is to conserve energy, avoid deterioration, and survive in the long term.

If that comes across as passive, so be it.

Healthy people often treat silence as a social problem. In severe paralysis, silence is frequently an energy-saving strategy. The same applies to limiting interaction, minimizing unnecessary procedures, or refusing activities that provide no direct benefit to survival or comfort.

Some caregivers complain about boredom when a patient does not perform emotional labor for them. Let them complain.

The ventilator patient is the one carrying the actual burden — every hour of every day, including the hours when the staff goes home and sleeps.

* * *

One of the most dangerous misunderstandings in ALS care is the idea that low oxygen saturation automatically means the patient simply needs more oxygen.

In many cases, the real problem is not oxygen intake but inadequate ventilation.

ALS weakens the respiratory muscles. The lungs themselves may remain relatively healthy, but the patient gradually loses the ability to move enough air. Carbon dioxide removal becomes impaired. Breathing effort increases. Eventually, ventilation becomes insufficient, even if oxygen transfer across the lungs remains reasonably intact.

A pulse oximeter measures oxygen saturation. It does not measure ventilation quality. It does not measure carbon dioxide. An ALS patient may therefore appear “acceptable” on oxygen saturation while carbon dioxide is already rising dangerously.

When supplemental oxygen is then added blindly, the numbers often improve. Staff feel reassured. The monitor looks better.

Meanwhile, the patient may be sliding into worsening hypercapnia.

The underlying respiratory failure has not been corrected. The patient is still underventilating. The body is simply receiving more oxygen despite inadequate air exchange. Carbon dioxide continues accumulating silently.

This can become lethal.

Carbon dioxide narcosis develops gradually. The patient becomes sleepy, confused, lethargic, and eventually unconscious. Because oxygen saturation may remain normal, the danger is sometimes missed until respiratory arrest occurs.

ALS patients die from this every year.

The problem is especially common outside specialized neuromuscular care. Emergency departments, ambulances, nursing homes, and general wards are trained to react aggressively to low oxygen saturation. In most diseases, that approach is reasonable. In neuromuscular respiratory failure, it can be dangerous if ventilation itself is not addressed simultaneously.

The proper treatment for hypoventilation is ventilation support.

That may mean:

- noninvasive ventilation
- invasive ventilation
- secretion clearance
- cough assist
- airway management
- correcting tube obstruction or positioning problems

Oxygen may still be needed in some situations, especially during pneumonia or severe lung disease. But oxygen alone is not a treatment for ventilatory failure.

In fact, blind oxygen administration can partially suppress the remaining respiratory drive in spontaneously breathing patients. Even more importantly, it may delay recognition of worsening respiratory failure because the monitor continues to display reassuring saturation values.

This is why capnography or blood gas measurements are often far more informative than pulse oximetry alone in ALS respiratory care. Carbon dioxide retention is frequently the real threat.

From an energy perspective, the situation is even more dangerous than it first appears. A patient struggling to breathe is already consuming enormous metabolic resources. Rising CO_2, poor sleep, respiratory muscle fatigue, secretion retention, and hypoxia together create a cascading systems failure. Simply raising oxygen saturation without unloading the respiratory system does little to stop that process.

The tragedy is that this type of death is often preventable.

ALS does not primarily destroy the lungs. It destroys the mechanics of breathing. Treating neuromuscular respiratory failure as if it were merely "low oxygen" fundamentally misunderstands the disease.

* * *

In healthcare, near misses are often treated as non-events. If the patient survives, if the tube was reconnected in time, if the oxygen drop was corrected before cardiac arrest, if the medication error was noticed before the syringe emptied, the incident quietly disappears. The system records success because the final outcome was acceptable. The role of luck is erased from the analysis.

This is the opposite of a real safety culture.

In industries that deal with unforgiving physics, near misses are treated as warnings from reality itself. In aviation or nuclear power, a valve left in the wrong position, an alarm misunderstood, or a procedure bypassed without consequence still triggers investigation. Not because damage occurred, but because the next time, luck may not intervene. The absence of casualties does not prove safety. It merely proves that the margin had not yet been fully consumed.

Healthcare too often works backward. Harm defines the seriousness of the event instead of the weakness of the barrier.

And when luck finally runs out, fatalities are described as unavoidable complications, unfortunate outcomes, progression of disease, or acts of God. Responsibility dissolves into statistics. The same patterns repeat because nobody was forced to confront them while they were still survivable.

The uncomfortable truth is that the system is not optimized for your long-term survival. It is optimized for throughput, legal defensibility, staffing limitations, and averages. A patient who quietly dies despite "appropriate care" fits into the machinery more easily than one who constantly questions procedures, monitors details, and demands safeguards against failure.

If you want to survive, especially with a severe chronic illness, you cannot passively assume that somebody else owns safety on your behalf.

You must build your own safety culture.

You must learn the equipment connected to your body. You must understand what each alarm means, what each tube does, what each setting controls, and which failure modes exist. You must notice recurring mistakes before they become fatal patterns. You must treat near misses as evidence of a weakened system, even when everybody else wants to move on from them. You must understand that "it has always been done this way" is not a safety argument.

Most importantly, you must stop confusing institutional calmness with actual safety.

Systems often become quietest immediately before disaster, because normalization occurs gradually. Small deviations become accepted. Temporary workarounds become routine. Missing redundancy becomes tolerated. Staff become accustomed to operating close to failure margins because catastrophes do not happen every day.

Until one day it does.

Survival in such an environment requires the mindset of an investigator rather than a passive recipient of care. Not because healthcare workers are evil, but because systems under constant overload inevitably drift toward accepting risk that should never have become normal.

* * *

One place where common practice often conflicts directly with long-term survival is hygiene.

People instinctively associate “good care” with showers, clean clothes, and routines that resemble normal life. But for a severely paralyzed ventilator patient, a shower is not a harmless comfort ritual. It is a major physical operation.

Every transfer carries risk.

The patient must be lifted, repositioned, disconnected or extended from equipment, moved through doorways, exposed to water and humidity, and then transferred back again. Tubes can kink. Ventilator circuits can disconnect. Secretions can suddenly obstruct airways during movement. Blood pressure may crash. Exhaustion accumulates afterward. Even without a dramatic accident, the body pays an energy price.

Healthy people underestimate how dangerous movement becomes once breathing depends on machinery.

For a ventilator patient, the objective is not to simulate a healthy life at any cost. The objective is survival with the least physiological stress possible.

From that perspective, bed wiping with alcohol-based or otherwise disinfecting towels is superior in nearly every practical sense.

The patient remains in a stable position.

Ventilation remains uninterrupted.

Transfers are avoided.

The procedure is faster, less exhausting, less equipment-intensive, and easier to repeat frequently. Skin can still be kept clean. Odors can still be controlled. Infection risk can even be lower because the entire operation is shorter and more controlled.

Most importantly, the patient is not subjected to a physically demanding event simply to satisfy the psychological expectations of what "proper hygiene" is supposed to look like.

Many practices around severe paralysis care are built around preserving appearances for healthy observers rather than minimizing cumulative risk for the patient.

A shower feels humane to outsiders because healthy people project their own preferences onto someone whose situation is fundamentally different.

But survival medicine is often about abandoning symbolic normality.

The body does not care whether hygiene looks dignified or familiar. It only cares how much strain was imposed, how many risks were introduced, and whether enough energy remained afterward to keep going another day.

* * *

Daily routine tasks involving ventilation pose one of the biggest risks to life, particularly if not recognized as such.

Ventilator filter replacement should be treated as a controlled transfer of life support rather than as a simple maintenance task. The danger is not the filter itself. The danger is reconnecting a ventilator that is not ventilating correctly after the circuit has been opened. In my experience, if left to the nurse alone, it happens about once every 100 days. If you don't take control of the procedure yourself, you'll be dead within a year.

During the procedure, you need to maintain continuous ventilation with a secondary device. A cough-assist device works well for this because it can provide large, clearly visible breaths independently of the ventilator being serviced.

Before disconnecting anything, the replacement filter and all required equipment should be prepared and within reach. Once the ventilator circuit is opened, delays increase the risk. The new filter should already be unpacked and oriented correctly so it can be inserted immediately.

The patient is first transferred from the ventilator to cough-assist support. Only after effective chest movement has been confirmed should the ventilator be turned off. This prevents a situation where ventilation is interrupted while troubleshooting is still ongoing.

After the filter is replaced and the ventilator is calibrated, it should not be connected directly back to the patient. Calibration errors, misassembled tubing, blocked filters, loose fittings, or failed startup states may leave the machine apparently running while delivering little or no effective ventilation. A patient with minimal autonomous breathing reserve may lose consciousness within minutes.

For that reason, functional testing should always be performed first using a rubber test lung. The ventilator is connected to the test lung and allowed to cycle normally. The test lung is preferably placed visibly on the patient's chest so that the patient can verify the delivered tidal movement directly. The purpose is not merely to verify airflow but to confirm that meaningful ventilation volume is actually being produced.

Only after proper expansion, pressure behavior, and alarm status have been confirmed should reconnection to the patient occur. Even then, chest movement should be observed again immediately after transfer.

The philosophy behind the procedure is simple: never trust status indicators alone when the consequence of failure is immediate hypoxia. Real airflow must be verified physically both before and after reconnecting life support.

What makes the routine important is that ventilator failures after circuit manipulation are often deceptively silent. Tubing may appear connected. The machine may appear active. Alarms may not trigger immediately. Yet effective ventilation may still be absent. The procedure, therefore, exists to force an independent verification step between maintenance work and patient reconnection.

19

On Supplements

No supplement has been shown to produce a definite, reproducible benefit in ALS. If one truly and reliably stopped progression, the evidence would already be impossible to ignore. That is the uncomfortable reality. Most supplements exist in a gray zone of weak evidence, conflicting studies, anecdotal reports, and plausible mechanisms that never translated into clear clinical outcomes.

Still, "not proven" is not the same thing as "impossible."

ALS is a disease where many known pathways converge on energy stress, oxidative damage, impaired protein handling, mitochondrial dysfunction, inflammation, and cellular exhaustion. It is therefore entirely plausible that some compounds may slightly improve resilience somewhere along that chain, even if the effect is too small, too subtype-specific, or too timing-dependent to emerge clearly in broad clinical trials. A treatment that helps one metabolic bottleneck may do little for another.

That makes supplementation less like treating a broken bone and more like trying to improve the operating margins of an overloaded system. The effects, if real, are likely incremental rather than dramatic. One should therefore be deeply skeptical of miracle claims, especially those built on testimonials, proprietary blends, or people selling certainty where none exists.

At the same time, the absence of definitive proof does not automatically make every attempt irrational. Many supplements have known biochemical roles, acceptable safety profiles, and at least some mechanistic plausibility. In a disease with few effective options, trying low-risk interventions may be reasonable, provided expectations remain realistic and critical thinking is not abandoned.

The danger is not merely wasting money. It is exhausting limited energy chasing endless protocols, interpreting every good or bad day as proof, and turning survival into a full-time optimization project. In ALS, energy itself is often the scarcest resource. Any intervention worth trying must justify the physical, mental, and logistical burden it adds.

This chapter, therefore, should not be read as a list of recommendations, but as a discussion of plausibility. Some compounds may help certain people. Some probably do nothing. Some may even be harmful. The problem is that medicine still does not know enough to cleanly separate those groups in advance.

* * *

First of all, some compounds may have practical benefits entirely separate from any hypothetical effect on ALS progression. N-acetylcysteine (NAC) is perhaps the clearest example. Even if it had no direct impact on the disease process, it can still be useful simply because it helps keep airway secretions thinner and easier to clear. In advanced ALS, where cough strength is impaired and respiratory reserve is limited, that alone may justify its use. Preventing mucus plugging and reducing the effort required for airway clearance are not trivial matters when breathing itself has become an energy-limited process.

Any additional biochemical benefits of NAC - such as supporting glutathione production and cellular antioxidant defenses - should therefore almost be viewed as secondary bonuses rather than the primary reason to take it. This distinction separates tangible symptomatic benefit from broader theoretical claims about slowing neurodegeneration.

That same logic appears repeatedly throughout this chapter. Some interventions may be worthwhile not because they cure ALS, but because they improve the operating conditions of a severely stressed system. In a disease where survival often depends on preserving narrow physiological margins, even small practical advantages can matter.

* * *

Coenzyme Q10 (CoQ10) is one of the more biologically plausible supplements discussed in ALS, even though clinical evidence has remained disappointing. Its appeal comes from its central role in mitochondrial energy production. Motor neurons are among the most energy-demanding cells in the body, and many ALS mechanisms appear to converge on impaired cellular energy balance. Anything supporting mitochondrial function, therefore, naturally attracts interest.

CoQ10 participates directly in the electron transport chain, where cells generate ATP. It also functions as an antioxidant within mitochondrial membranes, helping limit oxidative damage produced during energy metabolism. In theory, this makes it an attractive candidate for a disease characterized by both energy stress and oxidative injury.

The problem is that plausibility is not the same thing as demonstrated clinical benefit. Large studies have failed to show clear improvement in ALS progression or survival. That does not necessarily mean CoQ10 is useless. It may simply mean that any effect is too small, too subtype-specific, or too timing-dependent to emerge clearly in heterogeneous patient populations. A compound that slightly improves mitochondrial efficiency may not reverse a disease process already far advanced.

There is also the deeper systems-level question of whether mitochondrial dysfunction in ALS is a primary driver or merely a downstream consequence of already failing cellular homeostasis. Supporting mitochondria may help cells operate closer to their limits for longer, but it may not solve the upstream processes that pushed them there in the first place.

Still, CoQ10 remains one of the more rational supplements to consider within an energy-balance framework of ALS. Its mechanism is understandable, its safety profile is generally acceptable, and its biological role is real rather than speculative marketing language. The uncertainty lies not in whether CoQ10 matters biologically, but whether that contribution is large enough to alter outcomes in a meaningful way.

* * *

Creatine is one of the more plausible supplements in ALS because its entire biological role is energy buffering.

Cells do not consume ATP steadily. Demand fluctuates from moment to moment. A motor neuron firing rapidly or a muscle contracting suddenly may need energy faster than mitochondria can produce it. Creatine exists to smooth those peaks.

Inside cells, creatine is converted to phosphocreatine, which acts as a rapidly available energy reserve. When ATP levels begin to fall, phosphocreatine donates its phosphate group to ADP, regenerating ATP almost instantly. In effect, it is a short-term energy buffer system.

Phosphocreatine + ADP $\rightleftarrows$ Creatine + ATP

This is especially important in tissues with large and fluctuating energy demand, such as muscle and brain.

From an ALS perspective, the appeal is obvious. If motor neurons are living close to energetic collapse, even a small increase in buffering capacity might help them survive transient stress. During bursts of activity, hypoxia, excitotoxicity, or mitochondrial dysfunction, phosphocreatine may help stabilize ATP levels long enough to prevent catastrophic failure of ion pumps.

Creatine may also indirectly reduce excitotoxicity. When ATP falls, neurons lose the ability to maintain sodium, potassium, and calcium gradients. Membrane depolarization worsens glutamate release and calcium influx. Better energy buffering could, in theory, interrupt that spiral.

Muscle may benefit as well. ALS patients progressively lose muscle mass and strength, and weakened muscles become metabolically inefficient. Creatine can modestly improve muscular energy handling and water retention within muscle tissue. Even slight preservation of muscle function may reduce overall physiological strain.

Unfortunately, human ALS trials have shown disappointing results. Creatine proved relatively safe, but survival benefits were small or absent. That does not necessarily mean the underlying idea is wrong. ALS is probably too heterogeneous for a single metabolic supplement to produce dramatic effects across all patients. Timing may matter too. By the time a diagnosis is made, many motor neurons have already been permanently lost.

Still, creatine remains attractive because it directly targets a central weakness of the system: inadequate energy reserve. Unlike many speculative supplements, its mechanism is well understood and physiologically coherent.

It is also inexpensive, widely available, and generally safe at reasonable doses in people with normal kidney function. That alone makes it understandable why many ALS patients choose to try it despite limited evidence.

From an energy-balance viewpoint, creatine is not a cure and probably not even a major treatment. It is more like adding a slightly larger capacitor to an unstable electrical network. The underlying power plant may still be failing, but brief overloads become easier to survive.

* * *

Curcumin is another supplement that appears highly attractive on paper yet frustratingly uncertain in practice. It has been reported to affect a remarkably wide range of pathways relevant to ALS: oxidative stress, inflammation, mitochondrial dysfunction, protein aggregation, autophagy, and even stress granule dynamics. In cell cultures and animal models, curcumin often looks almost suspiciously beneficial.

The difficulty is that biology within a human body is far less cooperative than in a laboratory dish.

One major problem is bioavailability. Curcumin is poorly absorbed, rapidly metabolized, and reaches relatively low concentrations in tissues. This creates a recurring pattern seen throughout supplement research: strong mechanistic plausibility combined with weak or inconsistent clinical evidence. Many formulations, therefore, attempt to improve absorption, sometimes using piperine or lipid-based delivery systems, though this also complicates the interpretation of both efficacy and safety.

From an ALS perspective, the most interesting aspect of curcumin may be its broad systems-level behavior rather than any single molecular target. ALS does not appear to be driven by one isolated failure. It resembles a network collapse involving inflammation, impaired protein handling, oxidative stress, disrupted intracellular transport, mitochondrial strain, and chronic energy deficit. Curcumin is unusual in that it potentially touches many of those processes simultaneously.

That may sound appealing, but it also creates uncertainty. A compound that weakly affects many pathways may ultimately achieve little clinically measurable effect. Alternatively, subtle improvements across several interacting systems could together matter more than expected. Current evidence does not clearly answer that question.

Curcumin also illustrates an important psychological trap in ALS. The more complicated and multifaceted a disease appears, the easier it becomes to project hope onto compounds that "target everything." But a molecule that influences many signaling pathways does not necessarily mean it can overcome the large-scale structural failure occurring in degenerating motor neurons.

Still, within a low-risk supplementation strategy, curcumin remains one of the more understandable candidates to experiment with. Its biological rationale is coherent even if definitive evidence is lacking. As with many compounds discussed in this chapter, the strongest honest conclusion is not that it works, but that it remains plausible enough that complete dismissal would also be premature.

* * *

Acetyl-L-carnitine (ALCAR) is one of the more directly energy-related supplements considered in ALS. Its biological role is relatively straightforward: it helps transport fatty acids into mitochondria, where they can be used for ATP production. In other words, it participates directly in cellular energy metabolism rather than merely acting as a general antioxidant or anti-inflammatory compound.

That immediately makes it interesting in ALS. Motor neurons operate under extraordinary energy demands even under normal conditions. Their axons are extremely long, intracellular transport distances are vast, membrane potentials must be continuously maintained, and synaptic transmission itself is energetically expensive. If ALS fundamentally represents a failure of cellular energy balance, then compounds that support mitochondrial fuel utilization become at least mechanistically plausible.

ALCAR may also have secondary effects beyond its pure metabolic effects. Some studies suggest roles in mitochondrial stabilization, reduction of oxidative stress, maintenance of axonal transport, and modulation of excitotoxic injury. There are even hints of neurotrophic effects. None of these findings, however, translates into definitive proof of meaningful clinical benefit in ALS.

Still, compared to many supplements, the logic behind ALCAR is unusually coherent. It is not based on vague "wellness" language but on a direct connection to how cells generate usable energy. That does not mean it can stop degeneration. Supporting energy production in a failing neuron is not the same as correcting the upstream processes driving its failure. A cell already trapped in chronic protein aggregation, disrupted RNA handling, inflammatory stress, and impaired intracellular transport may still ultimately die despite somewhat improved metabolic support.

There is also a systems-level limitation worth remembering. If ALS progression partly reflects cells entering a state of chronic energetic insolvency, then improving fuel delivery may help only as long as sufficient functional cellular machinery remains. Once structural degeneration advances beyond a certain point, additional substrate cannot rescue a network that has already physically collapsed.

Nevertheless, among commonly discussed supplements, ALCAR fits naturally into an energy-balance interpretation of ALS. Its mechanism is understandable, biologically grounded, and at least directionally aligned with one of the central vulnerabilities of motor neurons. Whether that translates into clinically meaningful slowing of disease remains uncertain, but the rationale itself is difficult to dismiss outright.

* * *

TUDCA (tauroursodeoxycholic acid) is one of the few supplements in ALS that have progressed beyond purely theoretical discussion into genuine clinical interest. Unlike many compounds supported mainly by cell culture optimism, TUDCA has at least shown signals suggestive of possible clinical benefit, though the evidence still falls short of definitive proof.

Its appeal lies in targeting several processes that appear deeply relevant to motor neuron survival. TUDCA functions as a chemical chaperone, helping proteins fold properly and reducing stress within the endoplasmic reticulum. That matters because ALS increasingly appears linked to failures in protein handling, stress granule dynamics, and the accumulation of misfolded proteins, such as TDP-43 or SOD1 aggregates. A neuron overwhelmed by chronic protein stress also consumes enormous amounts of energy simply trying to maintain intracellular order.

TUDCA may additionally stabilize mitochondria, reduce apoptosis signaling, and dampen inflammatory pathways. From an energy-balance perspective, this is interesting because apoptosis can be viewed as a final cellular decision that continued operation is no longer energetically or structurally sustainable. A compound reducing the pressure toward that threshold is therefore at least mechanistically plausible.

Unlike many antioxidants, TUDCA also feels less like a vague attempt to “fight damage” and more like an intervention aimed at preserving cellular homeostasis. That distinction may matter. Motor neurons do not merely fail because reactive oxygen species exist. They fail because the systems maintaining order inside extremely large and energy-demanding cells gradually lose the ability to keep up.

Clinical evidence remains incomplete. Some earlier studies appeared promising, particularly in combination approaches, while later larger trials produced more ambiguous outcomes. That uncertainty does not necessarily invalidate the underlying biology. ALS heterogeneity again complicates interpretation. A treatment acting mainly on protein-handling stress may help certain pathological pathways more than others.

Among supplements and near-supplement compounds discussed in ALS, however, TUDCA remains one of the more scientifically credible candidates. It directly intersects with several central themes of neurodegeneration: protein folding stress, mitochondrial strain, apoptosis, and preservation of intracellular stability. Whether its effect is large enough to meaningfully alter long-term outcomes remains unresolved, but unlike many fashionable interventions, its rationale extends well beyond wishful thinking.

* * *

Nicotinamide riboside (NR) is interesting in ALS because it sits very close to the center of cellular energy metabolism itself. NR is a precursor to NAD+ (nicotinamide adenine dinucleotide), one of the most fundamental molecules involved in mitochondrial energy production, cellular repair, and metabolic regulation. Without sufficient NAD+, cells quite literally struggle to maintain life.

That immediately makes NR attractive within an energy-balance framework of ALS. Motor neurons are extraordinarily energy-demanding cells operating near physiological limits even under normal conditions. If ALS involves chronic energetic insolvency - whether driven by mitochondrial dysfunction, impaired transport, protein aggregation, oxidative stress, or inflammation - then declining NAD+ availability could plausibly worsen the situation further.

NAD+ is also tied to much more than ATP production alone. It affects DNA repair, stress responses, mitochondrial maintenance, autophagy, calcium homeostasis, and activity of sirtuins and PARP enzymes. This creates a recurring pattern seen throughout ALS biology: many apparently separate disease mechanisms converge back onto energy consumption and cellular resource allocation. A neuron constantly repairing oxidative and protein-folding damage may simply exhaust itself metabolically over time.

From that perspective, boosting NAD+ availability appears rational. The hope is not that NR somehow reverses degeneration, but that it slightly improves the metabolic reserves available to cells already under extreme strain.

The uncertainty lies in whether substrate availability is truly the limiting factor. Providing more NAD+ precursors only helps if the downstream machinery can still use them effectively. A heavily damaged neuron may resemble an engine failing from structural breakdown rather than fuel shortage alone. Increasing metabolic throughput might help stressed but still functional cells, yet accomplish little once degeneration becomes too advanced.

There is also a broader caution here. Compounds linked to "cellular energy" easily attract exaggerated claims because the concept sounds universally beneficial. But metabolism is not a simple battery that can merely be recharged indefinitely. Cells operate through tightly regulated networks where increasing one resource can shift burdens elsewhere. Biology rarely rewards simplistic optimization logic.

Still, NR remains one of the more intellectually coherent supplements within an ALS energy hypothesis. Its mechanism directly intersects with mitochondrial function and cellular stress management. Whether that translates into meaningful clinical benefit remains unknown, but the rationale itself is considerably stronger than for many compounds marketed to desperate patients.

* * *

The supplements listed above are the ones I use myself. None are clinically proven to produce definite benefit in ALS. All remain somewhat speculative. Still, each has at least a biologically plausible rationale, and none appear particularly harmful when used sensibly.

That is ultimately the position many ALS patients are forced into: operating in the space between complete evidence and complete ignorance.

At the same time, supplements should not distract from the far more important fundamentals. Maintaining sufficient nutrition matters vastly more than constructing elaborate supplement stacks. ALS patients are commonly pushed toward a chronic caloric deficit simply because eating, breathing, swallowing, coughing, and even remaining upright consume so much energy. Weight loss in ALS is rarely a good sign. The body is already struggling to maintain metabolic balance, and loss of reserve only narrows the margins further.

For that reason, an ALS patient should generally aim toward maintaining weight or even modest weight gain rather than pursuing restrictive diets or idealized notions of "healthy eating." In many chronic diseases excess weight is viewed as a problem. In ALS, lack of reserve is often the greater danger.

Avoiding unnecessary physical strain is equally important. Exercise does not build strength in denervated muscle the way it does in healthy physiology. Instead, overexertion may simply deepen the energy deficit already faced by vulnerable motor neurons. Remaining active within reasonable limits is sensible, but constantly pushing through exhaustion is not a virtue. In ALS, preserving function is often more important than testing its limits.

The central problem increasingly appears to be one of energy economics. Every intervention should therefore be judged not only by theoretical biochemical benefit, but by whether it improves or worsens the overall energy balance of the system trying to survive.

20

Research Issues

The history of the SOD1 mouse model begins in the early 1990s, shortly after mutations in the SOD1 gene were discovered to cause a familial form of ALS. At the time, this was a major breakthrough. ALS had long appeared mysterious and biologically inaccessible, but now there was at least one clearly identified genetic cause.

Researchers quickly engineered mice carrying mutant human SOD1 genes. The most famous became the G93A mouse, which overexpressed a mutant SOD1 protein and developed progressive paralysis followed by death. For the first time, scientists had an animal that visibly resembled ALS in a laboratory setting.

This transformed the field almost overnight.

Before that, ALS research had suffered from a lack of experimental models. Human motor neurons are difficult to study directly, and there was no easy way to reproduce the disease in animals. The SOD1 mouse solved that problem. Suddenly researchers could observe degeneration, test drugs, measure survival curves, and publish quantitative results.

The model became the backbone of preclinical ALS research.

But from the beginning there were warning signs.

Only a small fraction of ALS patients carry SOD1 mutations. Even in familial ALS, SOD1 represents only one subgroup. Most ALS patients instead show pathology dominated by TARDBP abnormalities, especially TDP-43 aggregation and nuclear depletion. Those findings became increasingly clear during the 2000s, but by then the SOD1 mouse infrastructure was already deeply entrenched.

Entire laboratories had been built around it. Grant systems expected it. Pharmaceutical companies used it as the standard entry gate for therapies. Reviewers trusted it because everyone else did.

And initially, it seemed to work.

Many interventions extended survival in SOD1 mice. Antioxidants helped. Anti-inflammatory approaches helped. Mitochondrial stabilizers helped. Gene silencing approaches helped. Dozens upon dozens of compounds produced promising mouse data.

Then the human trials began failing.

Again and again.

Some therapies showed no benefit whatsoever. Others produced tiny statistical effects with no meaningful clinical improvement. Many failed despite apparently robust preclinical evidence. The field responded by refining protocols, improving statistics, standardizing breeding methods, and increasing rigor in animal studies.

But the deeper problem was more uncomfortable to acknowledge.

What if the model itself was wrong for most ALS?

Over time, it became increasingly obvious that mutant SOD1 disease behaves differently from the more common TDP-43 forms of ALS. Even pathologically, they differ. Classical TDP-43 inclusions seen in sporadic ALS are often absent in SOD1 patients. The molecular cascades are not identical. The cellular stress responses differ. The protein aggregation behavior differs.

In effect, the field had spent decades optimizing therapies for one relatively rare subtype while hoping the results would generalize to all ALS cases.

The SOD1 mouse still had value. It was not useless. It taught researchers much about neuroinflammation, glial involvement, axonal degeneration, and protein misfolding toxicity. More recently, antisense therapies directly targeting mutant SOD1 finally produced some success precisely because they were aimed at the correct patient population rather than ALS as a whole.

But the broader lesson remains important.

A disease model is not the disease itself.

Once a scientific field becomes overly dependent on a single model organism, institutional momentum distorts reality. Funding flows toward what is measurable. Careers form around familiar techniques. Researchers learn to succeed within the model rather than question whether it truly represents the human condition.

And so ALS research spent decades curing mice while human patients continued to die.

* * *

The drug development pipeline in ALS has a structural flaw that borders on absurdity. Potential treatments are routinely screened in transgenic SOD1 mouse models and ranked based on whether they prolong survival in those animals. The problem is that SOD1 ALS represents only a small minority of human ALS cases, and even there, the disease mechanism is highly artificial compared to sporadic TDP-43 ALS. Yet the entire field behaves as if success or failure in that mouse determines whether a drug deserves to exist.

This creates a filtering system that is almost perfectly backward.

A treatment that genuinely improves the energy balance of stressed motor neurons in sporadic ALS may show little or no effect in a rapidly degenerating SOD1 mouse engineered to massively overexpress a mutant antioxidant enzyme. Such a compound is often discarded early because it "failed the model." In practice, the model may simply have been biologically irrelevant to the targeted mechanism.

At the same time, compounds that suppress some narrow downstream feature of the SOD1 mouse phenotype can appear spectacularly successful in preclinical studies even if they have little relevance to the broader ALS population. Those drugs advance into expensive human trials and then collapse because the human disease is not the same disease the mouse had.

The screening model, therefore, selects for treatments that fit the model rather than treatments that fit ALS itself.

This is made worse by the way the SOD1 mouse is constructed. The animals often harbor extremely high copy numbers of mutant SOD1 and develop disease at an accelerated rate. The resulting pathology is compressed, exaggerated, and heavily biased toward oxidative stress and protein toxicity pathways associated with that specific mutation. Human sporadic ALS is usually slower, more heterogeneous, and dominated by TDP-43 pathology instead.

From an engineering perspective, this approach is nonsensical. The field has effectively optimized itself around the wrong transfer function.

A candidate drug that stabilizes mitochondrial energy production, reduces stress granule persistence, improves autophagic efficiency, or decreases neuronal energy expenditure may be exactly what a slowly progressing TDP-43 patient needs. But if that effect does not rescue an overdriven SOD1 mouse racing toward paralysis in a few months, the compound is often terminated before meaningful human data is ever collected.

The consequence is deeply ironic:

- potentially useful drugs are killed because they do not work in a biologically distorted model
- biologically irrelevant drugs survive because they do work in that distorted model
- human trials then fail, reinforcing the illusion that ALS is uniquely untreatable

The problem may not be that ALS is impossible to treat. The problem may be that the filtering system preferentially removes the right answers before they ever reach patients.

* * *

ALS diagnosis is still often treated as a diagnosis of exclusion. In practice, that means months of ruling out everything else while the disease continues destroying motor neurons uninterrupted. From a biological standpoint, this is absurd.

By the time many patients finally receive a formal diagnosis, significant and irreversible neuronal loss has already occurred. Muscles have wasted, denervation has spread, compensatory mechanisms are failing, and the remaining neurons are already operating under extreme stress. Waiting for certainty may feel medically cautious, but biologically, it often means arriving after much of the damage is already done.

This creates a major problem for both clinical care and research.

For patients, delayed diagnosis means delayed interventions. Even supportive measures matter more early than late. Nutritional optimization, ventilation planning, secretion management, cough assist, energy conservation, communication systems, and prevention of repeated hypoxic or infectious stress all work better before the patient is already collapsing physiologically. The system often behaves as if supportive care can wait until "confirmed ALS," even though the disease itself does not wait.

For drug trials, the problem may be even worse. Many experimental therapies are probably tested far too late in the disease process. A treatment aimed at reducing protein aggregation, oxidative stress, excitotoxicity, transport failure, or inflammation may have little effect once the damage has progressed enough. That does not necessarily mean the therapy failed biologically. It may simply mean the intervention started after the irreversible phase had already progressed too far.

Imagine evaluating firefighting methods only after most of the building has already burned down. That is roughly how many ALS trials operate.

The exclusion-based diagnostic culture also biases research toward late-stage disease markers, as they are easiest to detect reliably. Earlier, subtle metabolic, inflammatory, transport, or electrophysiological abnormalities may persist for years before classical ALS becomes obvious enough to meet diagnostic criteria. But medicine tends to reward certainty over timing.

In rapidly progressive neurodegeneration, that tradeoff may be backward.

A false positive diagnosis is undesirable. But a perfectly certain diagnosis delivered after massive irreversible neuron loss is useless from a treatment point of view.

* * *

Prevalence is a bad metric for a disease that kills fast.

Prevalence does not measure how often people get the disease. It measures how many living people have it at a given moment. For a rapidly lethal disease, that number is automatically suppressed by death. Patients disappear from the statistic because they die, not because the disease is rare.

That makes prevalence a perverse metric in ALS. The better the care becomes, the more common ALS appears. Ventilation, feeding support, cough assist, better secretion management, and stubborn refusal to die all increase survival time. Increased survival time increases prevalence. Nothing about that means more people are getting ALS. It means fewer are being removed from the count.

So when ALS is described as rare based on prevalence, the statistic is partly measuring the historic failure to keep patients alive.

Incidence is the more honest number. It asks how many new people get ALS per year. That is the relevant metric for cause, risk, research priority, and drug development. On incidence, ALS no longer looks like some vanishingly exotic curiosity. It looks like a steady, brutal production line of new patients, most of whom are then rapidly erased from the prevalence statistics by death.

This matters because prevalence-based thinking makes ALS look smaller than it is. It hides the turnover. It hides the fact that a new cohort enters the machine every year. It also punishes survival: the moment patients live longer, the disease suddenly appears "more common," as if survival itself had created a problem.

No. The problem was always there.

Prevalence counts the living queue. Incidence counts the rate at which people are thrown into it. For ALS, incidence is the metric that tells the truth.

* * *

Clinicians often approach genetic screening for ALS primarily from a hereditary perspective.

The discussion usually revolves around questions like:
"Is this familial?"
"Can your children inherit it?"
"Should relatives be tested?"

Those are important questions, of course. But they are not the only reason genotype matters anymore.

Even today, before definitive cures exist, different ALS genotypes already provide clues about which biological pathways are failing inside the cell.

A mutation in SOD1 points to problems involving oxidative stress, protein misfolding, aggregation, and abnormal handling of reactive oxygen species.

C9orf72 suggests disturbances in RNA processing, nucleocytoplasmic transport, stress granule dynamics, autophagy, and toxic repeat-associated products.

TARDBP directly implicates TDP-43 dysfunction: impaired RNA regulation, nuclear depletion, abnormal phase separation, and aggregation.

FUS again shifts emphasis toward RNA metabolism and transport defects, but through somewhat different mechanisms.

These are not merely academic distinctions. They may determine which therapies have any chance of helping.

A drug aimed at oxidative damage may be more relevant in one subtype than another. A therapy targeting RNA toxicity may make little sense for a disease dominated by protein misfolding. Even supportive strategies may differ if one genotype produces especially aggressive metabolic stress or early respiratory involvement.

Yet many clinicians still implicitly treat ALS as one disease with one pathway, merely divided into “genetic” and “non-genetic” cases.

That framework is becoming outdated.

Increasingly, ALS appears more like a final common syndrome produced by multiple upstream failures. Different genetic variants push motor neurons toward collapse via distinct mechanisms, even if the clinical endpoint appears similar.

This also explains why so many “variant-independent” drug trials fail. If patients with fundamentally different molecular diseases are pooled into a single study population, any real signal may be lost in statistical noise.

The future of ALS treatment is unlikely to be one universal miracle drug.

More likely, treatment will gradually fragment into pathway-specific approaches guided by genotype, biomarkers, and cellular pathology. In that sense, genetic testing is no longer only about predicting inheritance.

It is becoming a way to identify which parts of the machinery are actually breaking down.

* * *

If your business is selling drugs, a cure is economically awkward. A cured patient ceases to be a customer. A drug that slows progression, prolongs life, or modestly improves function creates a continuing revenue stream instead. From a purely financial perspective, chronic management is often more attractive than eradication.

This does not require a conspiracy. It naturally emerges from the system's structure.

A pharmaceutical company is rewarded for stable long-term income, predictable markets, repeat prescriptions, and treatments that patients may use for years or decades. A cure works differently. Once the patient is cured, the market for that patient disappears. If the cure is highly effective, the entire market may gradually disappear.

For society, however, the calculation is almost the reverse. A cure returns people to a productive life. It reduces disability costs, hospitalizations, long-term care, caregiver burden, and the enormous economic losses created when people are removed from the workforce. Most importantly, it directly reduces human suffering rather than merely slowing its progression.

This tension becomes especially visible in diseases like Amyotrophic Lateral Sclerosis, where many existing drugs provide only modest benefits. From society's perspective, eliminating the disease entirely would be incomparably more valuable than extending survival by a few months. But scientifically, finding a true cure is harder, riskier, and more uncertain than developing drugs that slightly alter progression.

As a result, the goals overlap only partially. Patients want restoration. Society wants recovery. Companies are structurally rewarded for persistent treatment.

That does not mean pharmaceutical companies are evil. Without them, many important drugs would never exist. But it does mean society should not automatically assume that market incentives naturally optimize toward cures. Often, they optimize toward keeping disease survivable, manageable, and treatable for as long as possible.

That is why public research, universities, non-profit foundations, and increasingly AI-assisted open scientific work are so important. Society has interests that extend beyond recurring revenue.

21

My ALS Journey

ALS entered my life quietly at first. Not as a dramatic collapse, but as small inconsistencies that refused to go away. Loss of hand dexterity around 2010. Fingers no longer doing exactly what I wanted them to do. Tasks that once happened automatically started demanding concentration. At first, it was easy to dismiss. Stress. Fatigue. Aging. Something temporary.

But motor neurons do not negotiate.

The diagnosis came in 2012. Amyotrophic Lateral Sclerosis. Two weeks later, I became a father.

Life has a strange sense of timing sometimes.

While ALS was taking function away from me, a new human being had just entered the world, gaining it day by day. I watched the two curves unfold in opposite directions simultaneously. My child was learning to hold objects while my own hands were beginning to fail. First steps approaching while mine were disappearing. Speech was developing while mine was slowly becoming harder to produce.

ALS compresses time. Parenthood expands it.

Suddenly, the future mattered again, even while I was no longer sure how much of it belonged to me.

My wife carried a burden few people can truly understand. Almost immediately, she was taking care of both a newborn child and a husband with a progressive terminal disease. Those years blur together in my memory as a mix of exhaustion, hospitals, adaptive equipment, interrupted sleep, and ordinary family life somehow continuing amid all of it.

And still, life moved forward.

That remains one of the strangest aspects of ALS. Even while catastrophe unfolds inside one person, the outside world refuses to stop. Children grow. Seasons change. Bills arrive. People laugh at dinner tables. The contradiction feels almost offensive at first. Then, eventually, you realize it is probably what saves us.

The progression itself was brutal. By 2013, I was quadriplegic and dependent on eye-gaze communication systems. The speed of the collapse was difficult not only physically, but also psychologically. Modern culture teaches us that every problem has a solution if we just fight hard enough, stay optimistic enough, and search long enough. ALS does not cooperate with that narrative.

At some point, I realized that survival required abandoning the expectation of recovery.

That sounds darker than it is.

Giving up hope of getting better is not the same thing as giving up on life.

In some ways, it was liberating. Once the impossible objective was removed, attention could shift toward what still remained possible. Thought. Analysis. Writing. Observation. Contribution. I could no longer move, but I could still think. And thinking became my way forward.

Loss of lung function followed in 2015. Eventually, in 2017, I went on invasive ventilation. Many see that moment as the end of a story. For me, strangely enough, it was closer to stabilization.

By then, I had already spent years studying the disease obsessively, trying to understand why motor neurons fail in the first place. Not emotionally. Mechanistically.

I am not a doctor. I have no formal medical training. I approached ALS as an engineer confronting a hostile system that behaved according to rules not yet fully understood.

Over time, I became convinced that energy balance lies near the center of the disease.

And then something unexpected happened.

The progression stopped.

Not reversed. Not cured. The lost functions never returned. But after years of relentless decline, the disease stabilized around 2016 and has not resumed since. More than ten years without further progression. That experience does not prove a theory. But it is difficult to ignore either.

Living with ALS for this long changes your perspective. You stop measuring life against what healthy people expect from it. You learn that meaning is still possible far below the threshold where society assumes it disappears.

As my child gained independence, I lost mine.

But that did not make fatherhood meaningless. If anything, it made it sharper. More intentional. I understood very early that I might not have decades to emotionally postpone things. Small moments stopped being small. Watching cartoons together while unable to move anymore. Communicating through eye gaze while still trying to remain mentally present as a parent.

The disease took many things from me.

But it did not take away the fact that I became a father.

Epilogue

What makes ALS frightening is not only what it does to the body, but what it reveals about biology itself.

For a long time, medicine approached neurodegeneration largely from the perspective of isolated components. One protein. One mutation. One pathway. One toxic mechanism. And those details are not irrelevant. Biology is built from details.

But complex systems rarely fail because of a single thing.

Power grids collapse when multiple small disturbances align faster than stabilization systems can compensate. Industrial plants drift toward catastrophe when the maintenance burden slowly exceeds the available reserve. Financial systems fail when margins disappear and feedback loops begin to amplify each other. The final trigger often looks dramatic, but the real problem started much earlier, when the system quietly lost resilience.

Motor neurons may not be fundamentally different.

Throughout this book, I have repeatedly returned to the same idea from different directions: the balance between energy supply and the cost of maintaining order.

Stress granules.
Protein folding.
Axonal transport.
Mitochondrial function.
Excitotoxicity.
Inflammation.
Hypoxia.
Autophagy.
RNA handling.
Ventilation.
Sleep.
Nutrition.
Physical strain.

Different systems. Same underlying pressure.

A motor neuron is an extraordinarily ambitious structure. It maintains electrical stability across enormous distances, transports cargo continuously for decades, repairs itself constantly, suppresses molecular noise, recycles damaged components, and keeps functioning without replacement for an entire human lifetime.

Frankly, it is astonishing that these cells work at all.

Perhaps ALS is not one disease but many different ways of exhausting the same fragile system.

That possibility changes how one should think about treatment. Not as a search for one magical bullet against one isolated target, but as an attempt to restore enough reserve margin for the system to stabilize itself again.

And perhaps that is why so many therapies fail despite promising mechanisms. Biology is not organized according to academic specialties. The neuron does not care whether damage originated from protein aggregation, inflammation, mitochondrial dysfunction, impaired sleep, hypoxia, defective RNA handling, chronic stress, or transport failure. All of it eventually ends up in the same accounting system.

The energy budget must still balance.

At the same time, this book was never only about molecular biology.

It was also about adaptation.

Modern technology changed the meaning of paralysis. Communication no longer disappears when movement disappears. Eyegaze systems, ventilators, cough assist devices, environmental controls, and internet communication fundamentally altered what long-term survival can look like.

The healthcare system has not yet fully adapted to that reality.

For decades, severe paralysis often meant silence. Patients gradually vanished from public view. Now they remain present. They write, analyze, work, argue, organize, parent, and participate. They compare treatment practices internationally in real time. They describe directly what helps survival and what quietly destroys it.

We are no longer invisible.

That creates pressure for change, because systems built around passive decline struggle when patients become active participants again.

But ultimately, long-term survival alone is not the final solution.

The real solution is preventing these diseases in the first place.

And for the first time in history, that goal may no longer be unrealistic.

Humanity is entering an era in which AI-assisted biological analysis may finally be able to handle systems whose complexity exceeds unaided human intuition. Not because human intelligence is useless, but because the dimensionality of biology is enormous. The number of interacting pathways, feedback loops, compensatory mechanisms, and long-term state transitions is simply too large to mentally integrate reliably.

That may finally change.

If we can combine large-scale biological data, mechanistic understanding, and sufficiently powerful system-level analysis, diseases like ALS may eventually stop looking like mysterious acts of fate and become solvable engineering problems.

Difficult ones. But solvable.

I do not know whether the ideas in this book are correct in every detail. Some are certainly incomplete. Some may later prove wrong entirely. Biology has a habit of humiliating certainty.

But I strongly suspect the future of neurodegeneration research lies less in isolated molecular storytelling and more in understanding stressed biological systems as dynamic energy economies operating near critical stability limits.

And if that perspective turns out even partially correct, then perhaps the most important question is no longer:

“What kills the neuron?”

but:

“How do we help it maintain order long enough to survive?”

About the Author

Riku Mattila is a nuclear safety engineer by profession, not a physician or neuroscientist. His involvement with ALS began unwillingly, through his own diagnosis.

The first signs appeared in 2010 as a gradual loss of hand dexterity. Tasks that once required no thought became unreliable. Buttons, keyboards, tools, handwriting - all slowly deteriorated.

In 2012 came the diagnosis: Amyotrophic Lateral Sclerosis.

By 2013 the disease had progressed to quadriplegia, leaving him dependent on eye-gaze communication systems for writing and interaction with the outside world. The loss of movement did not end intellectual work, but it fundamentally changed the way it had to be done. Every sentence became slower. Every correction became deliberate.

In 2015 respiratory muscle weakness led to major loss of lung function. Invasive mechanical ventilation became necessary in 2017.

Yet the disease did something unexpected.

Progression appears to have stopped in 2016 and has not resumed since.

The author does not present this as proof of a cure, nor as medical advice. But after years spent studying ALS from the perspective of someone living inside it, he became convinced that the disease is deeply connected to cellular energy balance - especially in the most energy-demanding cells in the human body: motor neurons.

This book was not written from the perspective of detached academic observation, but from inside the disease itself - from years spent watching symptoms evolve, reading research, comparing hypotheses, and trying to understand why motor neurons fail. The author approaches ALS as an engineer approaches a difficult system failure: by looking for constraints, energy flows, hidden dependencies, and mechanisms that connect seemingly separate observations into a coherent whole.

He does not claim to have definitive answers. But he argues that many forms of ALS may ultimately converge on a common problem: an increasingly impossible energy balance within motor neurons, eventually pushing them past the point of recovery.

This book is an attempt to think about ALS differently.